Published in final edited form as:

Gene. 2020 February 05; 726: 144148. doi:10.1016/j.gene.2019.144148.

TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome

Anders O. Garlid^{1,2}, Calvin T. Schaffer^{1,2}, Jaewoo Kim^{1,2}, Hirsh Bhatt^{1,2}, Vladimir Guevara-Gonzalez^{1,5}, Peipei Ping^{1,2,3,4,6,†}

¹Cardiovascular Data Science Training Program at UCLA, University of California at Los Angeles, CA 90095, USA

²Department of Physiology, University of California at Los Angeles, CA 90095, USA

³Department of Medicine/Cardiology, University of California at Los Angeles, CA 90095, USA

⁴Department of Bioinformatics, University of California at Los Angeles, CA 90095, USA

⁵Department of Mathematics, University of California at Los Angeles, CA 90095, USA

⁶Scalable Analytics Institute (SCAI), University of California at Los Angeles, CA 90095, USA

Abstract

Tafazzin, which is encoded by the *TAZ* gene, catalyzes transacylation to form mature cardiolipin and shows preference for the transfer of a linoleic acid (LA) group from phosphatidylcholine (PC) to monolysocardiolipin (MLCL) with influence from mitochondrial membrane curvature. The protein contains domains and motifs involved in targeting, anchoring, and an active site for transacylase activity. Tafazzin activity affects many aspects of mitochondrial structure and function, including that of the electron transport chain, fission-fusion, as well as apoptotic signaling. *TAZ* mutations are implicated in Barth syndrome, an underdiagnosed and devastating disease that primarily affects male pediatric patients with a broad spectrum of disease pathologies that impact the cardiovascular, neuromuscular, metabolic, and hematologic systems.

[†]To Whom Correspondence Should be Addressed: Peipei Ping, Ph.D., FAHA, FISHR, UCLA David Geffen School of Medicine, Departments of Physiology, Medicine (Cardiology) and Bioinformatics, Suite 1-609 MRL Building, 675 Charles E. Young Dr. South, Los Angeles, CA 90095-1760, Phone: 310-267-5624, ppingucla@gmail.com.

CRediT (Contributor Roles Taxonomy) Document

Anders O. Garlid: Conceptualization; Data curation; Formal analysis; Methodology; Project administration; Software; Supervision; Validation; Roles/Writing - original draft; Writing - review & editing. Investigation; Visualization; Roles/Writing - original draft; Writing - review & editing.

Calvin T. Schaffer: Data curation; Roles/Writing - original draft.

Jaewoo Kim: Data curation; Roles/Writing - original draft.

Hirsh Bhatt: Data curation; Roles/Writing - original draft.

Vladimir Guevara-Gonzalez: Software; Visualization.

Peipei Ping: Conceptualization; Funding acquisition; Project administration; Resources; Supervision.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Competing Interests

The authors have no competing interests to declare.

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Keywords

mitochondrial biology; rare mitochondrial diseases; apoptosis; clinical case reports

1. Introduction

TAZ, also known as *G4.5*, is a 10kb gene located at position 28 on the q arm of chromosome X within a gene-rich, 450kb cluster of 13-16 small genes with CpG islands initially identified by Bione *et al.* as potential candidates for involvement in neuromuscular and cardiovascular disorders (Bione *et al.*, 1993; Bione *et al.*, 1996). *TAZ* encodes the transacylase protein tafazzin (Table 1), so named by Bione *et al.* based on a masochistic comic character named Tafazzi from an Italian sports show, apparently due to the difficulty they encountered in the original identification and characterization of this protein (Bione *et al.*, 1996). Tafazzin, located in the inner and outer mitochondrial membranes (IMM and OMM), acts as an acyl-specific transacylase that is essential to lipid metabolism through cardiolipin (CL) remodeling. CL remodeling, in turn, is essential for mitochondrial respiratory chain homeostasis, and disruptions to this process as a result of *TAZ* mutations have been shown to be a major cause of the complex, multi-system Barth syndrome. Mutations in the *TAZ* gene are associated with severe cardiovascular defects observed in Barth syndrome (BTHS), including endocardial fibroelastosis (EFE), X-linked dilated cardiomyopathy 3A (CMD3A), and left ventricular noncompaction (LVNC). As such, the gene is known by several aliases, including BTHS, EFE and EFE2, CMD3A, and LVNCX (Table 1). Due to unfortunate naming conventions, the *TAZ* gene and its tafazzin protein product have been confused in the literature with the *TAZ protein*, and *WWTR1* gene, which are associated with various cancers (NCBI, 2019). *TAZ* and tafazzin are not known to have any role in cancer. To date, there is no cure for Barth syndrome, and treatments for tafazzin deficiencies have focused on symptom-based management. Deeper investigation of *TAZ*, tafazzin, and cardiolipin is necessary to increase our collective understanding of mitochondrial biology and may help find treatments for Barth syndrome and mitochondrial myopathies.

2. Structure

Tafazzin is part of a superfamily of acyltransferases based on conserved regions and motifs identified through sequence alignment with other acyltransferase proteins involved in phospholipid biosynthesis (Neuwald, 1997; Acehan *et al.*, 2007). The crystal structure of tafazzin has not been determined by x-ray crystallography; the closest homologous protein is plant glycerol-3-phosphate acyltransferase (G3PAT) from *Cucurbita moscata* and *Spinacea oleracea* (PDB ID: 1IUQ) (Tamada *et al.*, 2004), which has just 18.1% sequence identity with human tafazzin (Waterhouse *et al.*, 2018). The half-life of tafazzin in mammalian cells is much shorter than that of many other mitochondrial proteins at only 3-6 hours (Xu *et al.*, 2015); the median half-life for mouse mitochondrial proteins is 17.2 days in the heart and 4.26 days in the liver (Kim *et al.*, 2012). This rapid turnover rate has likely contributed to the difficulty in elucidating the structure of tafazzin or acquiring a detailed understanding of its post-translational modifications (PTMs) from mass spectrometry data.

2.1. Tafazzin active site.

The putative phospholipid-binding site of human tafazzin is a 57 amino acid cleft with two open ends and a stretch of conserved, positively charged residues, based on homology modeling using ALAdeGAP for improved amino acid sequence alignment (Hijikata et al., 2011; Hijikata et al., 2015). Tafazzin and related hydrolases contain a conserved histidine residue required for their enzymatic action (Neuwald, 1997). In human tafazzin, His-69 (His-77 in yeast) and Asp-74 form part of a conserved HX₄D motif seen in acyltransferases composed of a histidine (His) and aspartic acid (Asp) separated by any 4 amino acids (X₄) (Heath and Rock, 1998; Xu et al., 2006; Abe et al., 2016). The HX₄D motif facilitates the Asp-His dyad mechanism seen commonly in serine proteases, whereby Asp raises the pK_a of His and aids the deprotonation of a hydroxyl group (Tang et al., 2018).

2.2. Mitochondrial localization and membrane anchoring.

Mitochondrial localization and membrane anchoring domains in tafazzin are of critical importance to its role in cardiolipin remodeling. In the H9c2 rat cardiomyocyte cell line, *TAZ* encodes two peptides external to the active site of the tafazzin protein that act independently to direct it to mitochondria (Dinca et al., 2018). The first of these sequences, encoded in exon 3 and spanning residues 84-95 on the tafazzin protein, targets exclusively to mitochondria, while the second, encoded in exon 7/8 and forming residues 185-220, also targets other cytosolic compartments (Dinca et al., 2018). The yeast *TAZ1* orthologue is homologous to human *TAZ* and has been used extensively to study the structure of tafazzin, its function, and in modeling Barth syndrome (Vaz et al., 2003; Gu et al., 2004; Ma et al., 2004; Claypool et al., 2006). In yeast, tafazzin has been shown to localize to membrane leaflets facing the intermembrane space (IMS) between the IMM and OMM, where it associates peripherally due to its lack of a transmembrane domain (Gawrisch, 2012; Abe et al., 2016). A hydrophobic sequence from residues 215-232 in yeast tafazzin confers its characteristic interfacial anchoring behavior in both the IMM and OMM (Herndon et al., 2013). Together, the translocase of the outer membrane (TOM) and the translocase of the inner membrane (TIM) facilitate tafazzin's movement across and insertion into the outer membrane, as well as its anchoring to inner membrane regions of intermediate density (Herndon et al., 2013).

2.3. *TAZ* mutations and effects on tafazzin structure.

In characterizing the mutations of a family of patients with Barth syndrome, many unique forms of tafazzin were identified based on differential splicing events, ranging in length from 129 to 292 amino acids and affecting regions throughout the protein (Bione et al., 1996). Many of the shorter forms of the protein lack a 30-residue hydrophobic N-terminus thought to contain a localization signal sequence, as well as modifications to the hydrophilic center of the protein in a 71 amino acid domain profuse with glycine and glutamic acid (Bione et al., 1996). Mutations within the localization region result in mistargeting that directs the protein into inner membrane leaflets facing the matrix, rather than facing the IMS (Herndon et al., 2013). Whited *et al.* categorized *TAZ* mutations into 7 functional classes based on the pathogenic loss-of-function mechanisms of each mutation (Whited et al., 2013). The largest class of mutations, Class 1, contains frameshift and splice-site mutations

along the length of the gene. Class 2 and 3 mutations are both found in the membrane anchor domain: Class 2 mutations, including V224R, V223D, and I226P variants, represent pleiotropic biochemical defects and often result in mitochondrial mistargeting, while Class 3 mutations (G230R) affect tafazzin macromolecular assembly. Class 4 mutations are composed primarily of missense mutations resulting in catalytically inactive tafazzin and Class 5 mutations, including L90P and N109V, encode hypomorphic alleles which retain transacylase activity. Class 6 mutations, including A88R and L148H, have folding and assembly defects, and Class 7 mutations result in temperature sensitive proteins that undergo activity loss before degradation. There is limited knowledge regarding a link between the different classes of *TAZ* mutations and disease severity. Whether tafazzin is rendered catalytically inactive, mistargeted, or incapable of membrane anchoring, there does not appear to be a clear distinction between phenotypic presentations of patients with different mutations. The diverse nature of *TAZ* mutations is clearly demonstrated in the expansive database maintained and regularly updated by the Barth Syndrome Foundation, which actively collects new data from healthcare professionals on both pathogenic and benign variants (<https://barthsyndrome.org/research/tazdatabase.html>). Mutations along the length of the *TAZ* gene, their frequency, and their pathogenicity (benign, pathogenic, or unknown effect) are depicted in Figure 1. Exonic, pathogenic variants along the length of the tafazzin protein, their frequency, and the type of genetic mutation from which they arise (deletion, frame shift, point mutation, or stop codon) are represented in Figure 2, along with the primary protein domains extracted from the literature.

3. Function

Tafazzin plays a critical role in cardiolipin remodeling, limits the structural diversity of CL molecular species, and restricts CL composition to two fatty acids, typically linoleic and oleic acids (Schlame, 2008). Tafazzin displays a preference for the transfer of linoleic acid (LA) from phosphatidylcholine (PC) to monolysocardiolipin (MLCL) and may be affected by and contribute to the negative curvature of the IMM and OMM (Schlame et al., 2017). Through its effects on CL, tafazzin impacts many aspects of mitochondrial structure-function, including inner membrane curvature, oxidative phosphorylation (OXPHOS), supercomplex formation, oxidative stress repair, apoptosis, and fission and fusion (Haines and Dencher, 2002; Schug and Gottlieb, 2009; Baile et al., 2014; Vernon et al., 2014; Frohman, 2015).

3.1. Transacylase activity.

Tafazzin is an acyl-specific transferase that catalyzes reversible acyl transfer reactions between phospholipids and lysophospholipids in a CoA-independent manner, playing a critical role in the deacylation-reacylation cycle of cardiolipin (Xu et al., 2006; Epand et al., 2015; Schlame et al., 2017). Generally, transacylases exhibit phospholipase activity and catalyze acylation and deacylation through a free enzyme acyl intermediate. Tafazzin, on the other hand, does not exhibit phospholipase activity, nor does it utilize the free enzyme acyl intermediate mechanism; it acylates and re-acylates, but deacylation occurs independently of tafazzin (Xu et al., 2006). After *de novo* synthesis of CL from phosphatidylglycerol by CL synthase (Crd1 in yeast, hCLS1 in humans) (Chen et al., 2006; Ye et al., 2016), the

remodeling process is initiated with cardiolipin deacylation to form MLCL by the cardiolipin specific phospholipase Cld1 in yeast (Beranek et al., 2009) or the calcium-independent phospholipase A2 (iPLA2) in humans (Mancuso et al., 2007a; Mancuso et al., 2007b; Malhotra et al., 2009; Yoda et al., 2010; Hsu et al., 2013). In order for MLCL produced by Cld1 to be exposed to tafazzin in the IMS, it must be transported through a different and unknown remodeling step (Baile et al., 2013). In mammals, tafazzin functions along with other enzymes to achieve CL remodeling, including MLCL acyltransferase (MLCLAT), acyl-CoA:lysocardiolipin acyltransferase (ALCAT), and phospholipase (Ye et al., 2016). Remodeling by tafazzin adds an acyl residue to immature CL, most frequently in the form of a linoleoyl residue in humans (Houtkooper et al., 2009b; Minkler and Hoppel, 2010). Tafazzin reacylates MLCL in a single-step acyl group transfer reaction (Figure 3) from a variety of phospholipids (PL), including CL, PC, phosphatidylethanolamine (PE), and phosphatidic acid (PA). Thus, tafazzin effectively acts as a shuttle for specific acyl groups between different phospholipids (Xu et al., 2006; Schlame, 2013).

3.2. Acyl specificity and sensing curvature.

Tafazzin shows a clear preference for the transfer of an LA group from PC to MLCL to form mature CL (Schlame et al., 2017). This remodeling process converts cardiolipin into a mature composition that contains a predominance of tetralinoleoyl moieties. This results in an enrichment of tetralinoleoyl-cardiolipin (CL₄) in the IMM (Houtkooper et al., 2009b). Indeed, Xu *et al.* report that, in *Drosophila melanogaster*, tafazzin can catalyze acyl transfer using multiple substrates, yet has a preference for the transfer of linoleoyl groups from PC to MLCL at a rate 10 times greater than that of oleoyl groups and twenty times greater than that of arachidonoyl groups, indicating a clear predilection for CL and PC substrates (Xu et al., 2006). Conflicting explanations for this preference have been proposed, namely that tafazzin has an inherent enzymatic preference for specific acyl residues, or that it acts on the basis of energy minimization and is influenced by the surrounding mitochondrial microenvironment. Abe *et al.* propose that tafazzin exhibits acyl specificity for the PC to MLCL reaction, and that its function is predominately centered on the transacylation of unsaturated acyl PC to MLCL under any conditions (Abe et al., 2016). Schlame *et al.*, on the other hand, propose the ‘thermodynamic remodeling’ hypothesis, whereby a perturbation of the lipid bilayer state and the physical properties of the lipid membrane determines tafazzin’s preference for specific acyl groups (Schlame et al., 2012; Epand et al., 2015). Schlame *et al.* propose that alternative phospholipases and acyltransferases (MLCAT and ALCAT), as well as the thermodynamic properties of lipids, provide the acyl specificity in CL remodeling and that tafazzin itself has no kinetic properties that suggest any sort of acyl-specificity. This mechanism proposes that since CL formation by tafazzin is reversible and has a minimal overall free energy, tafazzin’s role is to non-specifically transfer acyl groups among phospholipids to achieve optimal lipid composition and reduce the impact of membrane constraints (Schlame et al., 2012; Schlame et al., 2017).

According to the model proposed by Schlame *et al.* tafazzin specificity ultimately depends on the physical characteristics and packing properties of the lipid domain, including structural order and state. In *D. melanogaster*, tafazzin requires phospholipids that have a propensity to form non-bilayer phases such as HII phase, which is characterized by its

negative curvature, disorganized acyl chains, and low packing order (Schlame et al., 2012; Schlame et al., 2017). Stable lipid bilayers were found to have the lowest rate of reaction by tafazzin, while lipids in the hexagonal or micellar phases, which were characterized by packing order changes due to positive or negative curvature, had significantly higher reaction rates. In addition to the rate of reaction, curvature was also shown to determine the specificity of acyl transfer (Epand et al., 2015). The cristae of the IMM have negatively curved lipid monolayers and a predominance of phospholipids with small polar head groups, such as CL, and asymmetric, unsaturated hydrocarbon chains, such as linoleic acid. CL and linoleic acid specificity may thus be driven by curvature segregation of phospholipids based on physical properties of the lipid domains, which causes tafazzin to transacylate phospholipids that are located in negatively curved monolayers (Gawrisch, 2012; Schlame et al., 2012). In *Saccharomyces cerevisiae*, however, Abe *et al.* determined that tafazzin can efficiently catalyze a transacylation reaction even in a highly ordered lipid bilayer domain. Further, they posit that tafazzin has a unique acyl chain specificity for the PC to MLCL reaction in which tafazzin acts selectively to transfer PC's *sn*-2 acyl chain to MLCL's *sn*-1 and *sn*-2 positions. They determined that these reactions can occur in any environment, regardless of packing order and thermodynamic considerations (Abe et al., 2016). These studies illustrate the propensity of tafazzin to transfer a linoleoyl group from PC to MLCL; however, more research into the specific mechanisms is required to fully understand the process and specificity of tafazzin's actions. Further experiments with NMR analysis by groups such as Epand *et al.* may aid in elucidating these mechanisms due to its ability to probe curvature properties of lipid assemblies and observe structures with minor isotropic resonance (Epand et al., 2015).

3.3. Tafazzin and cardiolipin in mitochondrial structure and function.

Cardiolipin, modified by tafazzin, constitutes 13 - 20% of the total phospholipid mass and exhibits a cone-shaped structure that facilitates its distribution into mitochondrial cristae (Daum and Vance, 1997; Vernon et al., 2014). In the tafazzin-impaired fibroblasts of Barth syndrome patients, a greater proportion of saturated acyl chain substitution compromises this cone-shaped structure, and CL is heavily depleted with a concurrent accumulation of MLCL species (Oemer et al., 2018). CL assists in various aspects of OXPHOS, supporting the stability and function of the mitochondrial respiratory chain complexes through linkages between acyl chains (Houtkooper et al., 2009b). CL binds selectively to the c-rings of ATP synthase, which is required for the function and assembly of the ATP synthase. It also smooths the rotation (Mehdipour and Hummer, 2016) and facilitates dimerization for efficient ATP synthesis (Acehan et al., 2011). The structural properties of CL and its pK above 8 facilitate trapping proteins in the IMS. This is thought to achieve proton localization for ATP synthase function and minimization of pH fluctuations (Haines and Dencher, 2002). CL also interacts with other proteins such as the ATP/ADP translocase, pyruvate carrier, and carnitine carrier, assisted by glycerol bridges which enable flexibility for interaction with diverse surface shapes.

The lipid-to-protein mass ratio of OXPHOS complexes located in the mitochondrial cristae is 22:78 (Lotan and Nicolson, 1981), meaning that each complex is surrounded by just 40-400 lipid molecules (Xu et al., 2019). The molecular packing of lipids in a bilayer with

such a high protein density causes elastic stress on the curvature of the membrane (Brown, 2017). Tafazzin remodeling is triggered by OXPHOS complex assembly so as to mitigate this stress and stabilize the membrane by generating CL species with reduced free energy (Xu et al., 2019). The OXPHOS complexes I, III, and IV also form supercomplexes within the mitochondrial cristae such as the $I_1III_2IV_{n=1-4}$ “respirasome” (Schagger and Pfeiffer, 2000; Schagger, 2001; Stuart, 2008; Gu et al., 2016). CL is directly involved in the formation and maintenance of supercomplexes, providing structural support for trimer- and tetramerization (Zhang et al., 2002; Mileykovskaya and Dowhan, 2014). Furthermore, supercomplexes are disrupted and destabilized in Barth syndrome patients due to the loss of mature CL from the IMM (McKenzie et al., 2006).

Cardiolipin’s intimate association with the electron transport chain brings it into close proximity with reactive oxygen species (ROS) generated by OXPHOS complexes and which have been shown to target CL. The proximity and its enrichment in long-chain polyunsaturated fatty acid (PUFA) chains make CL susceptible to the attack. In the process of lipid peroxidation, highly reactive oxygen free radicals oxidize the fatty acid chains of CL to form lipid peroxides (Paradies et al., 2002). Oxidative damage leads to a loss of functional CL, a basis for mitochondrial dysfunction (Lesnefsky and Hoppel, 2008; Shi, 2010). CL remodeling removes and replaces acyl chains damaged by oxidative stress and is thought to play a key role in oxidative stress repair mechanisms (Baile et al., 2014) and the recovery of the normal oxidative functions of mitochondria (Baile et al., 2013). Aside from its damaging effects, ROS is also critical in mitochondrial and intracellular signaling, particularly in the context of cardioprotection from ischemia-reperfusion injury (Garlid, 2000). Phospholipids in the bilayer, such as cardiolipin, can be oxidized to form hydroperoxy fatty acids, which are hypothesized to carry the cardioprotective signal from mitochondria (Garlid et al., 2013).

CL forms membrane domains localized to negatively curved regions and induced by mitochondrial creatine kinase (mtCK) and cytochrome *c* that play critical roles in energy transfer, apoptosis, and functional recovery from ischemic insult (Laclau et al., 2001; Epand et al., 2007; Renner and Weibel, 2011). The microdomains occur at contact sites where the IMS narrows such that the IMM and OMM are positioned in close proximity to one another (Epand et al., 2007; Renner and Weibel, 2011; Pennington et al., 2018). The IMS at these contact sites is replete with mtCK, which induces their formation, recruits CL, and provides stabilization (Speer et al., 2005; Epand et al., 2007). Mature tetralinoleoyl-CL species generated by tafazzin remodeling are required for the formation of these domains and CL₄ depletion disrupts their formation, which may explain the mitochondrial impairment observed in Barth syndrome and cardiac ischemia-reperfusion injury (Sparagna et al., 2007; Paradies et al., 2015; Pennington et al., 2018). Further, mtCK is functionally coupled to adenine nucleotide translocase (ANT) in the IMM to facilitate efficient energy transfer by shuttling high-energy phosphates from the mitochondria to the cytosol through the voltage-dependent anion channel (VDAC) of the outer membrane (Laclau et al., 2001; Saks et al., 2006). During ischemia, for example, this IMS structure-function is disrupted, reducing the functional coupling of mtCK and ANT and increasing the permeability of the OMM to ADP, thereby limiting energy transfer processes and exacerbating damage from an ischemic event such as a heart attack (Laclau et al., 2001). The cardioprotective ischemic preconditioning (IPC) protocol opens the mitochondrial ATP-sensitive K⁺-channel (mitoK_{ATP}), which causes

matrix swelling and results in preservation of IMS volume, contact sites, and tight coupling between mtCK and ANT (Garlid, 2000; Laclau et al., 2001; Costa and Garlid, 2009). CL clustering at these contact sites is dependent on the octameric structure of mtCK, which readily binds to anionic phospholipids and may mediate intermembrane contact by binding to VDAC on the OMM (Epand et al., 2007).

Cardiolipin mediates apoptosis through its interactions with members of the Bcl-2 family, caspases, Bid, Bax, and Bak, with a direct impact on the apoptotic signaling cascade (Schug and Gottlieb, 2009). The total level of CL as well as the oxidative state of its acyl side chains directly impacts apoptosis by regulating cytochrome *c* mobilization; decreased CL content or oxidation of the normally unsaturated acyl side chains releases cytochrome *c* from the membrane (Schug and Gottlieb, 2009). This can be prevented with antioxidants (Petrosillo et al., 2003; Tyurina et al., 2006) and by the presence of mitochondrial redox proteins (Ran et al., 2004; Enoksson et al., 2005). Therefore, CL remodeling by tafazzin restores cytochrome *c* affinity for CL and its localization in the membrane by replacing oxidized fatty acids with non-oxidized acyl groups (Ye et al., 2016). Mobilized cytochrome *c* released from the mitochondrial membrane activates caspases 8 and 9, which cleave Bid to produce its truncated and active form, tBid (Kantari and Walczak, 2011). Once recruited by mitochondrial carrier homologue 2 (MTCH2), tBid activates apoptosis via Bax and Bak activation (Katz et al., 2012). Caspases 8 and 9, activate caspase 3, which drives apoptosis and inhibits ROS production (Brentnall et al., 2013). The apoptotic pathway is further amplified by this ROS inhibition, as it is a ROS signal that is responsible for protective mitoK_{ATP} opening that blocks the mitochondrial permeability transition (MPT) and prevents apoptosis (Costa and Garlid, 2008; Garlid et al., 2013).

Additionally, through interactions with both inner and outer mitochondrial membranes and proteins such as the GTPase Opa1, CL plays an important role in mitochondrial fission, fusion, and mitophagy (Frohmman, 2015; Hsu et al., 2015). *TAZ* deficiency reduces the generation of mitophagosomes and prevents initiation of mitophagy, further exacerbating the already reduced function of mitochondrial populations in *TAZ*-deficient organisms (Hsu et al., 2015). Under mitochondria-stress conditions, CL has been shown to promote mitochondrial fusion and membrane tethering with L-Opa1 and *trans*-Opa1, respectively, further illustrating its multifunctional importance in mitochondrial form and function (Ban et al., 2017).

4. Clinical Significance: Barth syndrome

Considering its critical role in the construction and maintenance of the IMM, it is of little surprise that *TAZ* has been implicated in a broad spectrum of disease pathologies that impact the cardiovascular, neuromuscular, metabolic, and hematologic systems. *TAZ* mutations are specifically associated with the multi-faceted Barth syndrome. An X-linked autosomal recessive disorder also known as 3-Methylglutaconic Aciduria Type II (3MGA2) (Barth et al., 1983; Aprikyan and Khuchua, 2013; Clarke et al., 2013). Characterized initially by Barth *et al.* in 1983 (Barth et al., 1983) as a uniformly lethal disease that affects only males, it has now been found that the age distribution ranges between 0 to 49 years, and symptoms peak around puberty (Barth et al., 2004). At least one female patient with BTHS has been

identified (Cosson et al., 2012). The Barth Syndrome Foundation reports that 151 living Barth patients have been identified up to 2012 and 10 new patients are diagnosed each year in the United States with no apparent racial or ethnic predilections. BTHS is estimated to appear in 1 out of every 300,000 to 400,000 live births, although predictions have suggested that the prevalence is actually closer to 1 out of every 140,000 live births as a result of the generally accepted notion that the disease is underdiagnosed (Cantlay et al., 1999; Barth Syndrome Foundation, 2019). In an effort to impose structure on otherwise unstructured clinical language contained in clinical case reports on BTHS (among other diseases), Caufield *et al.* extracted metadata from the reports and characterized patient symptomology using codes from the International Statistical Classification of Diseases and Related Health Problems (ICD-10) (Caufield et al., 2018b; Caufield et al., 2018a). The MitoCases platform (<http://mitocases.org/>) houses data on mitochondrial diseases, including Barth syndrome. Figure 4 displays the distribution of 997 instances of 206 unique ICD-10 codes represented across 54 clinical case reports covering 133 patients with BTHS, including top symptoms overall as well as top cardiovascular symptoms. Classifying Barth syndrome symptomology using ICD-10 codes has the potential to facilitate a greater understanding of the disease, its phenotypes, as well as to aid in diagnosis and treatment.

BTHS diagnosis and treatment is complicated and frequently delayed due to the complexity and variation of disease presentation. Early cardiomyopathy and hypertrophy combined with neutropenia (a low neutrophil count in the blood) is a hallmark of the disease, but confirmation of the diagnosis typically relies on genetic analysis of *TAZ*. Over 160 mutations or errors in the *TAZ* gene have been identified in BTHS patients, with a wide variety of onset, progression, and severity (Aprikyan and Khuchua, 2013). 3-methylglutaconic acid (3-MGA) and CL content levels are often used to identify BTHS, but they are not always a reliable indicator, which led some to propose using an HPLC-tandem mass spectrometry blood spot assay to measure the ratio of MLCL to CL₄. Although indirect, this highly specific biochemical measure of tafazzin function has the potential to provide a clinically valid method for BTHS diagnosis (Kulik et al., 2008; Houtkooper et al., 2009a; Bowron et al., 2015; Thompson et al., 2016). Combining biochemical analyses with physical tests, such as the 6-minute walk test (6MWT), may allow clinicians to determine the extent of the musculoskeletal impact and cardiac function in patients who survive infancy and those with unknown mitochondrial deficiencies. A combination of these procedures may help to improve diagnostic abilities and shape patient-specific treatment plans (Thompson et al., 2016).

4.1 Cardiovascular pathology.

Cardiomyopathy is a major characteristic of BTHS resulting from *TAZ* mutations. *TAZ* mutations lead to altered acyl chain composition and lipid peroxidation, and this can result in a failure of the sarcomeric action required to generate a sufficient power stroke. Disruption of the uniform contraction of sarcomeres can severely weaken the tissue, enlarge the left ventricular chamber, result in partial or incomplete contraction, and lead to decreased ejection volume. This results in the gradual thinning of the ventricular wall, stretching and dilation of cardiac chambers, and a cardiomyopathic phenotype of Barth syndrome, characterized by a weakened heart and diminished contractility (Barth et al., 2004; Ikon and

Ryan, 2017). Among all patients, about 95% exhibited a history of cardiomyopathy, with 41.5% of all diagnosed cardiomyopathies occurring from birth to one month of age. Furthermore, statistical analysis revealed that cardiac function of patients declines over time (Roberts et al., 2012). Contrary to ATP depletion, Wang *et al.* suggest ROS as the main cause of cardiomyocyte dysfunction and cardiovascular impairments such as defective sarcomere assembly and contractile stress (Wang et al., 2014). The typical approach to treating the cardiovascular symptoms of Barth syndrome is to follow the treatment paradigm for heart failure. This includes: 1) diuretics for fluid retention (e.g., spironolactone or furosemide), 2) angiotensin-converting enzyme (ACE) inhibitors for vasodilation to reduce afterload (e.g., captopril), 3) positive inotropes to increase contractility and as an antiarrhythmic (e.g., digoxin), and 4) beta blockers to reduce heart rate (e.g., propranolol, carvedilol). Regular echocardiography is used to monitor cardiovascular function and ejection fraction (McCanta et al., 2008; Masarone et al., 2017). Severe forms of cardiac symptoms in BTHS patients necessitate heart transplantation. Spencer *et al.* reported nine out of 73 (12%) patients referred to the BTHS Registry (<https://barthsyndromeregistry.patientcrossroads.org>) who have undergone cardiac transplantation are alive at the last update (Roberts et al., 2012; Clarke et al., 2013). Transplantation is generally successful (Clarke et al., 2013); among four BTHS patients described in Mangat *et al.*, one developed a severe infection but they did not show an increased rate of rejection and rated their quality of life as good (Ronghe et al., 2001; Mangat et al., 2007).

Cardiomyopathy in BTHS includes dilated cardiomyopathy (DCM) and left ventricular noncompaction (LVNC) (Barth et al., 2004). DCM is a specific type of cardiomyopathy characterized by an enlarged heart that is limited in function due to its inability to contract and pump blood efficiently (Araco et al., 2017; Soares et al., 2017). A patient with BTHS resulting from a c.83T>A mutation in tafazzin exhibited DCM with an ejection fraction of 30%, providing a direct association between the gene and DCM (Zapala et al., 2015). LVNC is a condition that exhibits prominent trabeculations and deep intertrabecular recesses in the left ventricle that resemble a spongy structure on the ventricular wall (Shemisa et al., 2013). One such case involves a family of 6 affected members that presented with LVNC with BTHS due to *TAZ* mutations (Bleyl et al., 1997). Isolated noncompaction of the ventricular myocardium (INVM) has also been found to affect the right ventricle and the interventricular septum (Bleyl et al., 1997; Barth et al., 2004). Despite the general occurrence of cardiomyopathy, there have been instances of BTHS caused by *TAZ* mutations with mild or late-onset cardiac involvement, as seen in Woiewodski *et al.* and again in Rigaud *et al.* Each discuss a cohort of BTHS patients exhibiting varying levels of cardiomyopathy, including two infantile patients who did not present with cardiomyopathy at the time of diagnosis (Woiewodski et al., 2017), another infantile patient whose autopsy revealed no cardiomyopathy, and one 12-year-old patient with no manifestation of cardiomyopathy (Rigaud et al., 2013). There is no clear structural or functional reason for the relatively mild presentations of certain patients, nor a direct mechanistic link between different mutations and disease presentations, representing an intriguing area of research necessary to glean a greater understanding of tafazzin and its role in disease.

4.2. Musculoskeletal pathology.

Although skeletal myopathy is often a typical characteristic of patients with disease-causing *TAZ* mutations, it manifests itself in a wide range of symptoms from nonexistent to severe. One of the most common musculoskeletal symptoms in BTHS patients is general and localized weakness. This includes overt muscle weakness and increased exertional fatigue due to skeletal myopathy and exaggerated by the cardiovascular complications associated with Barth syndrome (Spencer et al., 2011). Hypotonia, fatigue, and weakness can present early in life, persist, and may result in delayed motor development; most patients can walk unassisted by 2 years of age. Common phenotypes include short stature and facial dysmorphism and can extend to rarer phenotypes such as clubfoot (bilateral talipes) (Ades et al., 1993). Christodoulou *et al.* describes 6 cases of BTHS from four families with dysmorphic features, all of which exhibited persistent short stature. Four of the patients had also been found to exhibit similar myopathic facial appearances in conjunction with neuromuscular, cardiovascular and infectious symptoms (Christodoulou et al., 1994). A growth curve generated by examining 73 BTHS patients in Roberts *et al.* revealed a common down-shift in weight, length, and height relative to the normal population. Developmental delays are prevalent in BTHS patients with motor skills being the most affected, as indicated by a 65% prevalence of a delay in sitting up and a 71.6% delay in walking (Roberts et al., 2012).

Developmental delay has been treated with some success using cornstarch supplementation. This alternate source of glucose production ameliorates muscle wasting due to overnight fasting (Clarke et al., 2013). Other treatments, including oral arginine and carnitine supplementation, have centered on treating metabolic deficiencies, which improves cardiac function and muscle weakness in some patients (Ferreira et al., 1993; Rigaud et al., 2013; Vernon et al., 2014). However, while carnitine supplementation was initially offered as a treatment paradigm for all cases of BTHS (Ino et al., 1988), its effect has subsequently been called into question, and no formal assessment of the utility of arginine supplementation has been published. Thus far, both carnitine and arginine have demonstrated efficacy only in patients with those specific deficiencies (Ferreira et al., 1993; Rigaud et al., 2013; Vernon et al., 2014).

4.3. Neurological pathology.

Neurological complications tend to manifest as mild cognitive impairments in BTHS patients with *TAZ* mutations. While these patients were found to have a higher incidence of cognitive impairment (Mazzocco et al., 2007) and mild learning and speech difficulties (Roberts et al., 2012), many patients were found to have normal cognitive development, including a three-generation family with no cognitive impairment despite BTHS diagnosis (Ades et al., 1993). The limited neurologic involvement of BTHS is interesting given that tafazzin has been shown to play an important role in brain mitochondrial respiration and normal cognitive function (Cole et al., 2018). One postulate contends that the brain's reliance on glucose, over tissues in the heart and liver that require high mitochondrial activity, allows the brain to have a more diverse and less tetralinoleoyl-dependent CL composition. Reducing the need for highly symmetric remodeled tetralinoleoyl-CL to achieve sufficient mitochondrial function may allow the brain to mitigate or avoid the

detrimental effects of a tafazzin deficiency (Houtkooper et al., 2009b). Indeed, CL in the brain has higher amounts of arachidonic (AA) and docosahexaenoic (DHA) acids, distinct from the preference for tetralinoleoyl-CL seen in other tissues (Houtkooper et al., 2009b). Over 80% of CL in the liver and heart take the 18:2n-6 form, whereas the brain demonstrates less of a preference and has a higher concentration of saturated acyl chains, with only 48% polyunsaturated fatty acids and just 20% of its CL in the 18:2n-6 form (Corazzi and Roberti, 2009). It has also been proposed that the higher ROS scavenging capability of the brain, which is about 100 times higher than the rate of ROS generation (Starkov et al., 2014), may allow the brain to avoid the harmful effects more effectively than in other tissues even though it generates higher total levels of ROS (Cole et al., 2018).

4.4. Metabolic disorder.

3-methylglutaconic aciduria (3-MGA) is a major indicator of a variety of syndromes including BTHS, and is the result of mutations, including those in *TAZ*, that are linked to mitochondrial dysfunction (Su and Ryan, 2014). 3-MGA refers to increased levels of the organic acids 3-methylglutaconic acid, 3-methylglutaric acid, and 2-ethyl-hydracrylic acid in urine (Wortmann et al., 2012). BTHS patients typically demonstrate a large and consistent increase in the excretion of 3-MGA (Wortmann et al., 2013). A diagnosis of 3-MGA type II is synonymous with BTHS. While most BTHS patients exhibit varying severities of 3-MGA, a case report by Schmidt *et al.* describes a 15 year-old-boy with typical BTHS symptoms, such as dilated cardiomyopathy, but normal levels of organic acids, amino acids, and mucopolysaccharides in urine. Thus, there was no diagnosis of 3-MGA, despite a *TAZ* missense mutation in nucleotide 877 at exon 8 (Schmidt et al., 2004). Therapeutics such as riboflavin or coenzyme Q10 have been reported to show substantial improvement in some patients with 3-MGA (Wortmann et al., 2012). Overall, however, metabolic treatments vary between patients and are largely designed to target symptomatic deficiencies rather than the underlying cause of the disease (Clarke et al., 2013; Reynolds, 2015).

4.5. Hematologic pathology.

Neutropenia is one of the most frequent characteristics of BTHS caused by *TAZ* mutations, characterized by a decline in total number of circulating neutrophils accompanied by an increase in monocytes and eosinophils with no fluctuations in lymphocyte numbers (Clarke et al., 2013). Makaryan *et al.* found that neutropenia in BTHS is caused by a disruption of mitochondrial membrane potential as well as caspase-3 activation resulting in an increased rate of apoptosis of myeloid progenitor cells (Makaryan et al., 2009; Makaryan et al., 2012). Neutropenia is a particularly variant symptom, and can present itself in many different forms, from severe to mild, cyclical to non-cyclical, and intermittent to chronic (Steward et al., 2019). Severe chronic neutropenia (SCN), defined by an absolute neutrophil count of < 500/ μ L, is the most detrimental phenotype (Dale et al., 2006).

In a cohort study, Roberts *et al.* describe 73 patients with BTHS and indicate that 69.1% self-reported neutropenia with varying severity (Roberts et al., 2012). Ranging from a complete lack of neutrophils to a mild decline, neutropenia may be absent at presentation and change over the course of the disease in the same patient (Clarke et al., 2013). For instance, all seven members of a family with *TAZ* mutations exhibited no signs of

neutropenia (Ferri et al., 2015), while another case of siblings with severe BTHS both exhibited intermittent neutropenia (Bowron et al., 2015). Including persistent or intermittent forms of neutropenia, nearly 90% of BTHS patients exhibit the symptom to some degree (Clarke et al., 2013), though it is mentioned in just over 65% of available clinical case reports on Barth syndrome (Figure 4). Neutropenia is an immune system deficiency that results in diminished response to invading organisms. Therefore, decreased defense mechanisms leads to serious bacterial infections including prolonged upper respiratory tract infections, mouth ulcers (chronic aphthous stomatitis) due to *Candida* infections, inflamed gums and perianal dermatitis, as well as sepsis and multi-organ failure, which are frequently treated by prophylactic antibiotics (Barth et al., 2004; Dale et al., 2006; Clarke et al., 2013). Among 73 BTHS patients in Roberts *et al.*, 65% of those with neutropenia exhibited mouth ulcers, relative to only 35% of patients without neutropenia, while 28% had a history of pneumonia and 10% had a history of blood infections (Roberts et al., 2012). Granulocyte colony-stimulating factor (G-CSF) has been identified as an effective and safe treatment for SCN (Dale et al., 2006), leading to improvement in many BTHS patients with symptoms including aphthous ulcers, bacterial infections, and lethargy (Clarke et al., 2013).

4.6. Therapies in Barth syndrome.

Although several therapeutic strategies have proved successful in select clinical presentations, treatments are focused on treating the cardiovascular, musculoskeletal, and metabolic disorders, rather than the root cause of the disease. There is currently no cure for Barth syndrome (Barth Syndrome Foundation, 2019). Based on the observation that the fatty acid environment of cells impacts CL composition, ATP synthesis, membrane potential, and ROS production, dietary fatty acids have been suggested as a therapeutic strategy to target mitochondrial lipid metabolism and ameliorate effects on bioenergetics and cardiac function in mitochondrial diseases such as BTHS (Monteiro et al., 2013). It is unclear whether these treatments have significant effects in clinical practice. Direct modulation of CL content by lipid replacement therapy using CL nanodisks has also been tested in cell and animal models of Barth syndrome. Apoptosis induced by shRNA-mediated knockdown of *TAZ* in cultured HL60 myeloid progenitor cells (Makaryan et al., 2012) is attenuated by incubation with CL nanodisks and confers a significant increase in cellular CL content (Ikon et al., 2015). However, translation to an *in vivo* setting was unsuccessful, with no alteration in the CL profile of either wildtype mice or a *TAZ* knockdown mouse model of Barth syndrome (Ikon et al., 2018). Another study aimed to investigate whether overexpression of an alternate CL remodeling enzyme could restore CL in *TAZ*-deficient cells. Lymphoblasts from Barth syndrome patients transfected with *MLCLAT1* saw increased CL levels, improved mitochondrial basal respiration and proton leak, and reduced superoxide production, but only partial compensation for respiratory function and no restoration of OXPHOS supercomplex formation (Taylor et al., 2012; Mejia et al., 2018). These results show some promise, but it remains to be seen whether they can be recapitulated in a live animal model.

Elevated ROS and oxidative stress have been proposed as significant culprits in Barth syndrome and the development of cardioskeletal myopathy in these patients (Xu et al., 2005; Dudek et al., 2013; Saric et al., 2015). *In vitro* studies of *TAZ*-deficient cardiomyocytes treated with the mitochondrially-targeted Mito-Tempo antioxidant demonstrated improved

contractile function, cardiac hypertrophy, and cell death (He et al., 2014; Wang et al., 2014). Mice with *TAZ* deficiency (TAZKD) and mitochondria-specific overexpression of catalase, however, developed cardiomyopathy and muscle weakness similar to the Barth syndrome mouse, indicating that amelioration of oxidative stress is insufficient in the *in vivo* setting (Johnson et al., 2018).

Peroxisome proliferator-activated receptors (PPARs) and the PPAR-gamma coactivator-1 alpha (PGC-1 α) are central to energy metabolism and bioenergetics in mitochondria, presenting opportunities for treatment in a variety of mitochondrial and metabolic disorders. Bezafibrate is a fibric acid derivative pan-agonist of PPAR signaling pathways that activates oxidative metabolism genes (Huang et al., 2017). In patients with dyslipidemia or metabolic syndrome, bezafibrate reduces triglyceride levels and the incidence of myocardial infarction (Arbel et al., 2016). It also significantly decreases HbA1c in diabetic patients with dyslipidemia (Teramoto et al., 2012). Because of its role in mitochondrial bioenergetics, it has been proposed as a potential treatment for Barth syndrome as well. In a TAZKD mouse model with isoproterenol (iso) treatment to induce more significant cardiac dysfunction, bezafibrate rescued iso-induced heart failure with marked increases in left ventricular fractional shortening and ejection fraction and prevention of the development of cardiomyopathy (Huang et al., 2017). However, the treatment also caused a significant reduction in CL content and increase in MLCL/CL ratio in both wild type and *TAZ* knockdown mice, a common biomarker for Barth syndrome. Concurrently, mitochondrial biogenesis was amplified drastically, as indicated by a two-fold increase in mtDNA content and mitochondrial citrate synthase activity in bezafibrate-treated hearts. Additionally, the dose used in the mouse model was 60-80 times greater than is typically prescribed in dyslipidemic humans. The modification of CL content and dosage discrepancy presents significant hurdles to determine the mechanism of action, further evaluate the importance of MLCL and CL concentrations, and conduct toxicity studies before any enrollment in clinical trials (Huang et al., 2017).

Gene replacement therapy presents another avenue of exploration that has the potential to address underlying tafazzin deficiencies resulting from the *TAZ* mutations that cause Barth syndrome. Recombinant adeno-associated virus (rAAV) vectors provide stable and long-lasting gene transfer to the nucleus of an organism's cells using a non-pathogenic virus with minimal immune response (Schnepf et al., 2003). The successful application of an AAV-delivered gene therapy in spinal muscular atrophy also establishes an important precedent for the safety and efficacy of this approach in a clinic setting (Mendell et al., 2017). AAV serotype 9 (AAV9) demonstrates high affinity for the heart and skeletal muscle, making it ideal for application to Barth syndrome (Bish et al., 2008). In the TAZKD mouse model of Barth syndrome, an AAV9-*TAZ* vector with a desmin promoter resulted in significant *TAZ* gene and tafazzin protein expression levels in the heart and muscle and minimal levels in the liver (Suzuki-Hatano et al., 2019a). Measures of muscular strength and fatigue as well as whole body activity (e.g., exercise and distance travelled) of the treated mice improved significantly. Increased fractional shortening and ejection fraction as well as decreased heart weight/body weight ratio indicate significant improvements in cardiac function. Mitochondrial structure and function defects were ameliorated, with improved cristae and sarcomeric organization, greater numbers and size, as well as improved mitochondrial

respiration and OXPHOS complex activity (Suzuki-Hatano et al., 2019a). In further studies, multiplex tandem mass tagging-based proteomics has provided a deeper mechanistic insight into the progression of Barth syndrome and its impact on critical proteins involved in cardiac development, heart failure, transcription, translation, and carnitine biosynthesis. (Suzuki-Hatano et al., 2019b). The striking result of AAV9- *TAZ* gene therapy across a range of treatment ages in the mouse model of Barth syndrome paints an optimistic picture for its potential as a future clinical option for these patients.

Elamipretide (MTP-131, SS-31, Bendavia) is a novel mitochondria-targeted tetrapeptide designed to temporarily bind to CL and protect it from oxidative damage by blocking CL-mediated conversion of cytochrome *c* into a peroxidase, thereby preserving cristae structure, promoting OXPHOS, and maintaining mitochondrial integrity (Birk et al., 2014; Szeto, 2014). In the canine model of intracoronary microembolization-induced chronic heart failure (Sabbah et al., 1991), long-term therapy with elamipretide was demonstrated to improve left ventricular ejection fraction, normalize key plasma biomarkers including tumor necrosis factor- α (TNF- α) and C-reactive protein (CRP), and reverse mitochondrial deficiencies in the heart (Sabbah et al., 2016) and skeletal muscle (Sabbah et al., 2019). In explanted human cardiac ventricular tissue from patients with a wide demographic range, elamipretide improved impaired mitochondrial function in heart failure and had no effect on normal mitochondrial function in nonfailing hearts. Additionally, supercomplex function was improved, but no change was observed in the activities of OXPHOS complexes II or V (Chatfield et al., 2019). In a clinical trial for patients with heart failure with reduced ejection fraction (HFrEF), elamipretide was safe, well-tolerated, and achieved significant decreases in left ventricular end-diastolic volume (LVEDV) and end-systolic volume (LVESV) in the highest dose cohort. Ejection fraction also improved in the treatment group as compared to those administered a placebo, though the measures did not reach statistical significance (Daubert et al., 2017). Elamipretide is currently in Phase 2 clinical trials (TAZPOWER) to treat Barth syndrome specifically, and recruitment is in progress for a Phase 3 clinical trial (MMPOWER-3) in patients with primary mitochondrial myopathies ([ClinicalTrials.gov](https://clinicaltrials.gov) [Internet]). The previous animal studies and clinical trials in heart failure bode well for successful applications of Elamipretide in the Barth syndrome and mitochondrial myopathy patient populations.

5. Conclusions

Tafazzin is a transacylase responsible for remodeling cardiolipin in the mitochondrial membrane and plays an integral role in maintaining mitochondrial structure and function. The tight bends of the cristae in the inner membrane require a specific acyl profile, afforded by the activity of tafazzin. The protein has targeting and anchoring domains that direct it to the IMM and OMM and position it to face the IMS, build mature, tetra-linoleoyl cardiolipin species, and repair damaged membranes. Mutations in *TAZ* produce a dysfunctional or improperly localized protein that causes Barth syndrome, a multi-factorial and devastating disease that presents in infancy and results in heart failure, neutropenia, and musculoskeletal abnormalities. Current therapeutic paradigms are wide-ranging and attempt to treat the symptoms of individual systems. No cure exists for Barth syndrome, though there are a number of different treatments in development aimed at modulating metabolic processes,

reducing oxidative stress, protecting CL from degradation, as well as conducting targeted gene-replacement of *TAZ*. Additional studies are necessary to fully characterize and understand the unique and integral role of tafazzin in mitochondrial biology and in the manifestation of Barth syndrome.

Acknowledgements

The authors would like to acknowledge the support of National Institutes of Health (T32 EB16640 to Anders O. Garlid, R35 HL135772 to Peipei Ping), and the Theodore C. Laubisch endowment at UCLA to Peipei Ping. The authors are grateful to Keith Garlid and Hirsh Bhatt for their significant contributions and revisions to this manuscript, as well as Erik Lontok from the Barth Syndrome Foundation for his invaluable input.

This review and the corresponding Gene Wiki article are written as part of the Gene Wiki Review series – a series resulting from a collaboration between the journal GENE, the Gene Wiki Initiative, and the BD2K initiative. The Gene Wiki Initiative is supported by National Institutes of Health (R01 GM089820, U54 GM114833). Additional support for Gene Wiki Reviews is provided by Elsevier, the publisher of GENE. The corresponding Gene Wiki entry for this review can be found here: <https://en.wikipedia.org/wiki/tafazzin/>.

Abbreviations

3-MGA	3-methylglutaconic aciduria
AA	arachidonic acid
aa	amino acid
rAAV	recombinant adeno-associated virus
AAV9	adeno-associated virus serotype 9
ACE	angiotensin-converting enzyme
ALCAT	acyl-CoA:lysocardiolipin acyltransferase
ANT	adenine nucleotide translocase
BTHS	Barth syndrome
CL	cardiolipin
CL₄	tetralinoleoyl-cardiolipin
CMD3A	cardiomyopathy, dilated 3A (X-linked)
DCM	dilated cardiomyopathy
DHA	docosahexaenoic acid
EFE2	endocardial fibroelastosis 2
G3PAT	glycerol-3-phosphate acyltransferase
G-CSF	granulocyte colony-stimulating factor
HFrEF	heart failure with reduced ejection fraction
IMM	inner mitochondrial membrane

IMS	intermembrane space
INVM	isolated noncompaction of the ventricular myocardium
iPLA2	calcium-independent phospholipase A2
LA	linoleic acid
LVEDV	left ventricular end-diastolic volume
LVESV	left ventricular end-systolic volume
LVNC	left ventricular noncompaction
mitoK_{ATP}	mitochondrial ATP-sensitive K ⁺ -channel
MLCL	monolysocardiolipin
MLCLAT	monolysocardiolipin acyltransferase
mtCK	mitochondrial creatine kinase
nt	nucleotide
OMM	outer mitochondrial membrane
OXPHOS	oxidative phosphorylation
PA	phosphatidic acid
PC	phosphatidylcholine
PE	phosphatidylethanolamine
PL	phospholipids
PPAR	peroxisome proliferator-activated receptor
PGC-1α	PPAR-gamma coactivator-1alpha
PUFA	polyunsaturated fatty acid
ROS	reactive oxygen species
SCN	severe chronic neutropenia
TIM	translocase of the inner membrane
TOM	translocase of the outer membrane
VDAC	voltage-dependent anion channel

References Cited

- Abe M, Hasegawa Y, Oku M, Sawada Y, Tanaka E, Sakai Y and Miyoshi H, 2016 Mechanism for Remodeling of the Acyl Chain Composition of Cardiolipin Catalyzed by *Saccharomyces cerevisiae* Tafazzin. *J Biol Chem* 291, 15491–502. doi: 10.1074/jbc.M116.718510. [PubMed: 27268057]

- Acehan D, Malhotra A, Xu Y, Ren M, Stokes DL and Schlame M, 2011 Cardiolipin affects the supramolecular organization of ATP synthase in mitochondria. *Biophys J* 100, 2184–92. doi: 10.1016/j.bpj.2011.03.031. [PubMed: 21539786]
- Acehan D, Xu Y, Stokes DL and Schlame M, 2007 Comparison of lymphoblast mitochondria from normal subjects and patients with Barth syndrome using electron microscopic tomography. *Lab Invest* 87, 40–8. doi: 10.1038/labinvest.3700480. [PubMed: 17043667]
- Ades LC, Gedeon AK, Wilson MJ, Latham M, Partington MW, Mulley JC, Nelson J, Lui K and Sillence DO, 1993 Barth syndrome: clinical features and confirmation of gene localisation to distal Xq28. *Am J Med Genet* 45, 327–34. doi: 10.1002/ajmg.1320450309. [PubMed: 8434619]
- Aprikyan AA and Khuchua Z, 2013 Advances in the understanding of Barth syndrome. *Br J Haematol* 161, 330–8. doi: 10.1111/bjh.12271. [PubMed: 23432031]
- Araco M, Merlo M, Carr-White G and Sinagra G, 2017 Genetic bases of dilated cardiomyopathy. *J Cardiovasc Med (Hagerstown)* 18, 123–130. doi: 10.2459/JCM.0000000000000432. [PubMed: 27661610]
- Arbel Y, Klempfner R, Erez A, Goldenberg I, Benzekry S, Shlomo N, Fisman EZ, Tenenbaum A and Group BIPS, 2016 Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. *Cardiovasc Diabetol* 15, 11. doi: 10.1186/s12933-016-0332-6. [PubMed: 26794137]
- Baile MG, Sathappa M, Lu YW, Pryce E, Whited K, McCaffery JM, Han X, Alder NN and Claypool SM, 2014 Unremodeled and remodeled cardiolipin are functionally indistinguishable in yeast. *J Biol Chem* 289, 1768–78. doi: 10.1074/jbc.M113.525733. [PubMed: 24285538]
- Baile MG, Whited K and Claypool SM, 2013 Deacylation on the matrix side of the mitochondrial inner membrane regulates cardiolipin remodeling. *Mol Biol Cell* 24, 2008–20. doi: 10.1091/mbc.E13-03-0121. [PubMed: 23637464]
- Ban T, Ishihara T, Kohno H, Saita S, Ichimura A, Maenaka K, Oka T, Mihara K and Ishihara N, 2017 Molecular basis of selective mitochondrial fusion by heterotypic action between OPA1 and cardiolipin. *Nat Cell Biol* 19, 856–863. doi: 10.1038/ncb3560. [PubMed: 28628083]
- Barth PG, Scholte HR, Berden JA, Van der Klei-Van Moorsel JM, Luyt-Houwen IE, Van 't Veer-Korthof ET, Van der Harten JJ and Sobotka-Plojhar MA, 1983 An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. *J Neurol Sci* 62, 327–55. [PubMed: 6142097]
- Barth PG, Valianpour F, Bowen VM, Lam J, Duran M, Vaz F.d.r.M. and Wanders RJA, 2004 X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): An update. *American Journal of Medical Genetics* 126A, 349–354. doi: 10.1002/ajmg.a.20660. [PubMed: 15098233]
- Barth Syndrome Foundation, 2019 What is Barth Syndrome? Barth Syndrome Foundation.
- Beranek A, Rechberger G, Knauer H, Wolinski H, Kohlwein SD and Leber R, 2009 Identification of a cardiolipin-specific phospholipase encoded by the gene CLD1 (YGR110W) in yeast. *J Biol Chem* 284, 11572–8. doi: 10.1074/jbc.M805511200. [PubMed: 19244244]
- Bione S, D'Adamo P, Maestrini E, Gedeon AK, Bolhuis PA and Toniolo D, 1996 A novel X-linked gene, G4.5, is responsible for Barth syndrome. *Nat Genet* 12, 385–9. doi: 10.1038/ng0496-385. [PubMed: 8630491]
- Bione S, Tamanini F, Maestrini E, Tribioli C, Poustka A, Torri G, Rivella S and Toniolo D, 1993 Transcriptional organization of a 450-kb region of the human X chromosome in Xq28. *Proc Natl Acad Sci U S A* 90, 10977–81. [PubMed: 8248200]
- Birk AV, Chao WM, Bracken C, Warren JD and Szeto HH, 2014 Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. *Br J Pharmacol* 171, 2017–28. doi: 10.1111/bph.12468. [PubMed: 24134698]
- Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G, Wilson JM and Sweeney HL, 2008 Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. *Hum Gene Ther* 19, 1359–68. doi: 10.1089/hum.2008.123. [PubMed: 18795839]

- Bleyl SB, Mumford BR, Brown-Harrison MC, Pagotto LT, Carey JC, Pysher TJ, Ward K and Chin TK, 1997 Xq28-linked noncompaction of the left ventricular myocardium: prenatal diagnosis and pathologic analysis of affected individuals. *Am J Med Genet* 72, 257–65. [PubMed: 9332651]
- Bowron A, Honeychurch J, Williams M, Tsai-Goodman B, Clayton N, Jones L, Shortland GJ, Qureshi SA, Heales SJ and Steward CG, 2015 Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype. *J Inher Metab Dis* 38, 279–86. doi: 10.1007/s10545-014-9747-y. [PubMed: 25112388]
- Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E and Boise LH, 2013 Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. *BMC Cell Biol* 14, 32. doi: 10.1186/1471-2121-14-32. [PubMed: 23834359]
- Brown MF, 2017 Soft Matter in Lipid-Protein Interactions. *Annu Rev Biophys* 46, 379–410. doi: 10.1146/annurev-biophys-070816-033843. [PubMed: 28532212]
- Cantlay AM, Shokrollahi K, Allen JT, Lunt PW, Newbury-Ecob RA and Steward CG, 1999 Genetic analysis of the G4.5 gene in families with suspected Barth syndrome. *J Pediatr* 135, 311–5. [PubMed: 10484795]
- Caufield JH, Zhou Y, Garlid AO, Setty SP, Liem DA, Cao Q, Lee JM, Murali S, Spendlove S, Wang W, Zhang L, Sun Y, Bui A, Hermjakob H, Watson KE and Ping P, 2018a Data from: A reference set of curated biomedical data and metadata from clinical case reports. *Dryad Digital Repository*. doi: 10.5061/dryad.r36cn90.
- Caufield JH, Zhou Y, Garlid AO, Setty SP, Liem DA, Cao Q, Lee JM, Murali S, Spendlove S, Wang W, Zhang L, Sun Y, Bui A, Hermjakob H, Watson KE and Ping P, 2018b A reference set of curated biomedical data and metadata from clinical case reports. *Sci Data* 5, 180258. doi: 10.1038/sdata.2018.258. [PubMed: 30457569]
- Chatfield KC, Sparagna GC, Chau S, Phillips EK, Ambardekar AV, Aftab M, Mitchell MB, Sucharov CC, Miyamoto SD and Stauffer BL, 2019 Elamipretide Improves Mitochondrial Function in the Failing Human Heart. *JACC Basic Transl Sci* 4, 147–157. doi: 10.1016/j.jacbs.2018.12.005. [PubMed: 31061916]
- Chen D, Zhang XY and Shi Y, 2006 Identification and functional characterization of hCLS1, a human cardiolipin synthase localized in mitochondria. *Biochem J* 398, 169–76. doi: 10.1042/BJ20060303. [PubMed: 16716149]
- Christodoulou J, McInnes RR, Jay V, Wilson G, Becker LE, Lehotay DC, Platt BA, Bridge PJ, Robinson BH and Clarke JT, 1994 Barth syndrome: clinical observations and genetic linkage studies. *Am J Med Genet* 50, 255–64. doi: 10.1002/ajmg.1320500309. [PubMed: 8042670]
- Clarke SL, Bowron A, Gonzalez IL, Groves SJ, Newbury-Ecob R, Clayton N, Martin RP, Tsai-Goodman B, Garratt V, Ashworth M, Bowen VM, McCurdy KR, Damin MK, Spencer CT, Toth MJ, Kelley RI and Steward CG, 2013 Barth syndrome. *Orphanet J Rare Dis* 8, 23. doi: 10.1186/1750-1172-8-23. [PubMed: 23398819]
- Claypool SM, McCaffery JM and Koehler CM, 2006 Mitochondrial mislocalization and altered assembly of a cluster of Barth syndrome mutant tafazzins. *J Cell Biol* 174, 379–90. doi: 10.1083/jcb.200605043. [PubMed: 16880272]
- [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT03098797) [Internet]. Identifier [NCT03098797](https://clinicaltrials.gov/ct2/show/study/NCT03098797): A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome (TAZPOWER). National Library of Medicine (US), Bethesda, MD.
- Cole LK, Kim JH, Amoscato AA, Tyurina YY, Bay RH, Karimi B, Siddiqui TJ, Kagan VE, Hatch GM and Kauppinen TM, 2018 Aberrant cardiolipin metabolism is associated with cognitive deficiency and hippocampal alteration in tafazzin knockdown mice. *Biochim Biophys Acta Mol Basis Dis* 1864, 3353–3367. doi: 10.1016/j.bbadis.2018.07.022. [PubMed: 30055293]
- Corazzi L and Roberti R, 2009 Lipids of Brain Mitochondria, in: Lajtha A, Tettamanti G and Goracci G (Eds.), *Handbook of Neurochemistry and Molecular Neurobiology: Neural Lipids*. Springer US, Boston, MA, pp. 199–221. doi: 10.1007/978-0-387-30378-9_8.
- Cosson L, Toutain L, Simard G, Kulik W, Matyas G, Guichet A, Blasco H, Maakaroun-Vermesse Z, Vaillant MC, Le Caignec C, Chantepie A and Labarthe F, 2012 Barth syndrome in a female patient. *Mol Genet Metab* 106, 115–20. doi: 10.1016/j.ymgme.2012.01.015. [PubMed: 22410210]

- Costa AD and Garlid KD, 2008 Intramitochondrial signaling: interactions among mitoKATP, PKCepsilon, ROS, and MPT. *Am J Physiol Heart Circ Physiol* 295, H874–82. doi: 10.1152/ajpheart.01189.2007. [PubMed: 18586884]
- Costa AD and Garlid KD, 2009 MitoKATP activity in healthy and ischemic hearts. *J Bioenerg Biomembr* 41, 123–6. doi: 10.1007/s10863-009-9213-y. [PubMed: 19353252]
- Dale DC, Bolyard AA, Schwinzer BG, Pracht G, Bonilla MA, Boxer L, Freedman MH, Donadieu J, Kannourakis G, Alter BP, Cham BP, Winkelstein J, Kinsey SE, Zeidler C and Welte K, 2006 The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report. *Support Cancer Ther* 3, 220–31. doi: 10.3816/SCT.2006.n.020. [PubMed: 18632498]
- Daubert MA, Yow E, Dunn G, Marchev S, Barnhart H, Douglas PS, O'Connor C, Goldstein S, Udelson JE and Sabbah HN, 2017 Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. *Circ Heart Fail* 10. doi: 10.1161/CIRCHEARTFAILURE.117.004389.
- Daum G and Vance JE, 1997 Import of lipids into mitochondria. *Prog Lipid Res* 36, 103–30. [PubMed: 9624424]
- Dinca AA, Chien WM and Chin MT, 2018 Identification of novel mitochondrial localization signals in human Tafazzin, the cause of the inherited cardiomyopathic disorder Barth syndrome. *J Mol Cell Cardiol* 114, 83–92. doi: 10.1016/j.yjmcc.2017.11.005. [PubMed: 29129703]
- Dudek J, Cheng IF, Balleininger M, Vaz FM, Streckfuss-Bomeke K, Hubscher D, Vukotic M, Wanders RJ, Rehling P and Guan K, 2013 Cardiolipin deficiency affects respiratory chain function and organization in an induced pluripotent stem cell model of Barth syndrome. *Stem Cell Res* 11, 806–19. doi: 10.1016/j.scr.2013.05.005. [PubMed: 23792436]
- Enoksson M, Fernandes AP, Prast S, Lillig CH, Holmgren A and Orrenius S, 2005 Overexpression of glutaredoxin 2 attenuates apoptosis by preventing cytochrome c release. *Biochem Biophys Res Commun* 327, 774–9. doi: 10.1016/j.bbrc.2004.12.067. [PubMed: 15649413]
- Epand RF, Tokarska-Schlattner M, Schlattner U, Wallimann T and Epand RM, 2007 Cardiolipin clusters and membrane domain formation induced by mitochondrial proteins. *J Mol Biol* 365, 968–80. doi: 10.1016/j.jmb.2006.10.028. [PubMed: 17097675]
- Epand RM, D'Souza K, Berno B and Schlame M, 2015 Membrane curvature modulation of protein activity determined by NMR. *Biochim Biophys Acta* 1848, 220–8. doi: 10.1016/j.bbamem.2014.05.004. [PubMed: 24835017]
- Ferreira C, Thompson R and Vernon H, 1993 Barth Syndrome, in: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K and Amemiya A (Eds.), *GeneReviews*((R)). Seattle (WA).
- Ferri L, Donati MA, Funghini S, Cavicchi C, Pensato V, Gellera C, Natacci F, Spaccini L, Gasperini S, Vaz FM, Cooper DN, Guerrini R and Morrone A, 2015 Intra-individual plasticity of the TAZ gene leading to different heritable mutations in siblings with Barth syndrome. *Eur J Hum Genet* 23, 1708–12. doi: 10.1038/ejhg.2015.50. [PubMed: 25782672]
- Frohman MA, 2015 Role of mitochondrial lipids in guiding fission and fusion. *J Mol Med (Berl)* 93, 263–9. doi: 10.1007/s00109-014-1237-z. [PubMed: 25471483]
- Garlid AO, Jaburek M, Jacobs JP and Garlid KD, 2013 Mitochondrial reactive oxygen species: which ROS signals cardioprotection? *Am J Physiol Heart Circ Physiol* 305, H960–8. doi: 10.1152/ajpheart.00858.2012. [PubMed: 23913710]
- Garlid KD, 2000 Opening mitochondrial K(ATP) in the heart--what happens, and what does not happen. *Basic Res Cardiol* 95, 275–9. [PubMed: 11005581]
- Gawrisch K, 2012 Tafazzin senses curvature. *Nat Chem Biol* 8, 811–2. doi: 10.1038/nchembio.1068. [PubMed: 22987008]
- Gu J, Wu M, Guo R, Yan K, Lei J, Gao N and Yang M, 2016 The architecture of the mammalian respirasome. *Nature* 537, 639–43. doi: 10.1038/nature19359. [PubMed: 27654917]
- Gu Z, Valianpour F, Chen S, Vaz FM, Hakkaart GA, Wanders RJ and Greenberg ML, 2004 Aberrant cardiolipin metabolism in the yeast taz1 mutant: a model for Barth syndrome. *Mol Microbiol* 51, 149–58. doi: 10.1046/j.1365-2958.2003.03802.x. [PubMed: 14651618]
- Haines TH and Dencher NA, 2002 Cardiolipin: a proton trap for oxidative phosphorylation. *FEBS Lett* 528, 35–9. [PubMed: 12297275]

- He Q, Harris N, Ren J and Han X, 2014 Mitochondria-targeted antioxidant prevents cardiac dysfunction induced by tafazzin gene knockdown in cardiac myocytes. *Oxid Med Cell Longev* 2014, 654198. doi: 10.1155/2014/654198. [PubMed: 25247053]
- Heath RJ and Rock CO, 1998 A conserved histidine is essential for glycerolipid acyltransferase catalysis. *J Bacteriol* 180, 1425–30. [PubMed: 9515909]
- Herndon JD, Claypool SM and Koehler CM, 2013 The Taz1p transacylase is imported and sorted into the outer mitochondrial membrane via a membrane anchor domain. *Eukaryot Cell* 12, 1600–8. doi: 10.1128/EC.00237-13. [PubMed: 24078306]
- Hijikata A, Yura K, Noguti T and Go M, 2011 Revisiting gap locations in amino acid sequence alignments and a proposal for a method to improve them by introducing solvent accessibility. *Proteins* 79, 1868–77. doi: 10.1002/prot.23011. [PubMed: 21465562]
- Hijikata A, Yura K, Ohara O and Go M, 2015 Structural and functional analyses of Barth syndrome-causing mutations and alternative splicing in the tafazzin acyltransferase domain. *Meta Gene* 4, 92–106. doi: 10.1016/j.mgene.2015.04.001. [PubMed: 25941633]
- Houtkooper RH, Rodenburg RJ, Thiels C, van Lenthe H, Stet F, Poll-The BT, Stone JE, Steward CG, Wanders RJ, Smeitink J, Kulik W and Vaz FM, 2009a Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome. *Anal Biochem* 387, 230–7. doi: 10.1016/j.ab.2009.01.032. [PubMed: 19454236]
- Houtkooper RH, Turkenburg M, Poll-The BT, Karall D, Perez-Cerda C, Morrone A, Malvagia S, Wanders RJ, Kulik W and Vaz FM, 2009b The enigmatic role of tafazzin in cardiolipin metabolism. *Biochim Biophys Acta* 1788, 2003–14. doi: 10.1016/j.bbame.2009.07.009. [PubMed: 19619503]
- Hsu P, Liu X, Zhang J, Wang HG, Ye JM and Shi Y, 2015 Cardiolipin remodeling by TAZ/tafazzin is selectively required for the initiation of mitophagy. *Autophagy* 11, 643–52. doi: 10.1080/15548627.2015.1023984. [PubMed: 25919711]
- Hsu YH, Dumlao DS, Cao J and Dennis EA, 2013 Assessing phospholipase A2 activity toward cardiolipin by mass spectrometry. *PLoS One* 8, e59267. doi: 10.1371/journal.pone.0059267. [PubMed: 23533611]
- Huang Y, Powers C, Moore V, Schafer C, Ren M, Phoon CK, James JF, Glukhov AV, Javadov S, Vaz FM, Jefferies JL, Strauss AW and Khuchua Z, 2017 The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome. *Orphanet J Rare Dis* 12, 49. doi: 10.1186/s13023-017-0605-5. [PubMed: 28279226]
- Ikon N, Hsu FF, Shearer J, Forte TM and Ryan RO, 2018 Evaluation of cardiolipin nanodisks as lipid replacement therapy for Barth syndrome. *J Biomed Res* 32, 107–112. doi: 10.7555/JBR.32.20170094. [PubMed: 29336355]
- Ikon N and Ryan RO, 2017 Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy. *Lipids* 52, 99–108. doi: 10.1007/s11745-016-4229-7. [PubMed: 28070695]
- Ikon N, Su B, Hsu FF, Forte TM and Ryan RO, 2015 Exogenous cardiolipin localizes to mitochondria and prevents TAZ knockdown-induced apoptosis in myeloid progenitor cells. *Biochem Biophys Res Commun* 464, 580–5. doi: 10.1016/j.bbrc.2015.07.012. [PubMed: 26164234]
- Ino T, Sherwood WG, Cutz E, Benson LN, Rose V and Freedom RM, 1988 Dilated cardiomyopathy with neutropenia, short stature, and abnormal carnitine metabolism. *J Pediatr* 113, 511–4. [PubMed: 3411399]
- Johnson JM, Ferrara PJ, Verkerke ARP, Coleman CB, Wentzler EJ, Neuffer PD, Kew KA, de Castro Bras LE and Funai K, 2018 Targeted overexpression of catalase to mitochondria does not prevent cardioskeletal myopathy in Barth syndrome. *J Mol Cell Cardiol* 121, 94–102. doi: 10.1016/j.yjmcc.2018.07.001. [PubMed: 30008435]
- Kantari C and Walczak H, 2011 Caspase-8 and bid: caught in the act between death receptors and mitochondria. *Biochim Biophys Acta* 1813, 558–63. doi: 10.1016/j.bbame.2011.01.026. [PubMed: 21295084]
- Katz C, Zaltsman-Amir Y, Mostizky Y, Kollet N, Gross A and Friedler A, 2012 Molecular basis of the interaction between proapoptotic truncated BID (tBID) protein and mitochondrial carrier

- homologue 2 (MTCH2) protein: key players in mitochondrial death pathway. *J Biol Chem* 287, 15016–23. doi: 10.1074/jbc.M111.328377. [PubMed: 22416135]
- Kim TY, Wang D, Kim AK, Lau E, Lin AJ, Liem DA, Zhang J, Zong NC, Lam MP and Ping P, 2012 Metabolic labeling reveals proteome dynamics of mouse mitochondria. *Mol Cell Proteomics* 11, 1586–94. doi: 10.1074/mcp.M112.021162. [PubMed: 22915825]
- Kulik W, van Lenthe H, Stet FS, Houtkooper RH, Kemp H, Stone JE, Steward CG, Wanders RJ and Vaz FM, 2008 Bloodspot assay using HPLC-tandem mass spectrometry for detection of Barth syndrome. *Clin Chem* 54, 371–8. doi: 10.1373/clinchem.2007.095711. [PubMed: 18070816]
- Laclau MN, Boudina S, Thambo JB, Tariosse L, Gouverneur G, Bonoron-Adele S, Saks VA, Garlid KD and Dos Santos P, 2001 Cardioprotection by ischemic preconditioning preserves mitochondrial function and functional coupling between adenine nucleotide translocase and creatine kinase. *J Mol Cell Cardiol* 33, 947–56. doi: 10.1006/jmcc.2001.1357. [PubMed: 11343417]
- Lesnefsky EJ and Hoppel CL, 2008 Cardiolipin as an oxidative target in cardiac mitochondria in the aged rat. *Biochim Biophys Acta* 1777, 1020–7. doi: 10.1016/j.bbabi.2008.05.444. [PubMed: 18515061]
- Lotan R and Nicolson GL, 1981 Plasma membranes of eukaryotes, Van Nostrand-Reinhold, Princeton, NJ.
- Ma L, Vaz FM, Gu Z, Wanders RJ and Greenberg ML, 2004 The human TAZ gene complements mitochondrial dysfunction in the yeast taz1Delta mutant. Implications for Barth syndrome. *J Biol Chem* 279, 44394–9. doi: 10.1074/jbc.M405479200. [PubMed: 15304507]
- Makaryan V, Dror Y and Aprikyan AA, 2009 Loss of Tafazzin (TAZ) Function and Accelerated Apoptosis of Human Bone Marrow Stem and Myeloid Progenitors in Barth Syndrome. *Blood* 114, 549.
- Makaryan V, Kulik W, Vaz FM, Allen C, Dror Y, Dale DC and Aprikyan AA, 2012 The cellular and molecular mechanisms for neutropenia in Barth syndrome. *Eur J Haematol* 88, 195–209. doi: 10.1111/j.1600-0609.2011.01725.x. [PubMed: 22023389]
- Malhotra A, Edelman-Novemsky I, Xu Y, Plesken H, Ma J, Schlame M and Ren M, 2009 Role of calcium-independent phospholipase A2 in the pathogenesis of Barth syndrome. *Proc Natl Acad Sci U S A* 106, 2337–41. doi: 10.1073/pnas.0811224106. [PubMed: 19164547]
- Mancuso DJ, Han X, Jenkins CM, Lehman JJ, Sambandam N, Sims HF, Yang J, Yan W, Yang K, Green K, Abendschein DR, Saffitz JE and Gross RW, 2007a Dramatic accumulation of triglycerides and precipitation of cardiac hemodynamic dysfunction during brief caloric restriction in transgenic myocardium expressing human calcium-independent phospholipase A2gamma. *J Biol Chem* 282, 9216–27. doi: 10.1074/jbc.M607307200. [PubMed: 17213206]
- Mancuso DJ, Sims HF, Han X, Jenkins CM, Guan SP, Yang K, Moon SH, Pietka T, Abumrad NA, Schlesinger PH and Gross RW, 2007b Genetic ablation of calcium-independent phospholipase A2gamma leads to alterations in mitochondrial lipid metabolism and function resulting in a deficient mitochondrial bioenergetic phenotype. *J Biol Chem* 282, 34611–22. doi: 10.1074/jbc.M707795200. [PubMed: 17923475]
- Mangat J, Lunnon-Wood T, Rees P, Elliott M and Burch M, 2007 Successful cardiac transplantation in Barth syndrome--single-centre experience of four patients. *Pediatr Transplant* 11, 327–31. PMID: 17430492. doi: 10.1111/j.1399-3046.2006.00629.x. [PubMed: 17430492]
- Masarone D, Valente F, Rubino M, Vastarella R, Gravino R, Rea A, Russo MG, Pacileo G and Limongelli G, 2017 Pediatric Heart Failure: A Practical Guide to Diagnosis and Management. *Pediatr Neonatol* 58, 303–312. doi: 10.1016/j.pedneo.2017.01.001. [PubMed: 28279666]
- Mazzocco MM, Henry AE and Kelly RI, 2007 Barth syndrome is associated with a cognitive phenotype. *J Dev Behav Pediatr* 28, 22–30. doi: 10.1097/01.DBP.0000257519.79803.90. [PubMed: 17353728]
- McCanta AC, Chang AC and Weiner K, 2008 Cardiomyopathy in a child with neutropenia and motor delay. *Curr Opin Pediatr* 20, 605–7. doi: 10.1097/MOP.0b013e32830a990a. [PubMed: 18781126]
- McKenzie M, Lazarou M, Thorburn DR and Ryan MT, 2006 Mitochondrial respiratory chain supercomplexes are destabilized in Barth Syndrome patients. *J Mol Biol* 361, 462–9. doi: 10.1016/j.jmb.2006.06.057. [PubMed: 16857210]

- Mehdipour AR and Hummer G, 2016 Cardiolipin puts the seal on ATP synthase. *Proc Natl Acad Sci U S A* 113, 8568–70. doi: 10.1073/pnas.1609806113. [PubMed: 27439859]
- Mejia EM, Zegallai H, Bouchard ED, Banerji V, Ravandi A and Hatch GM, 2018 Expression of human monolysocardiolipin acyltransferase-1 improves mitochondrial function in Barth syndrome lymphoblasts. *J Biol Chem* 293, 7564–7577. doi: 10.1074/jbc.RA117.001024. [PubMed: 29563154]
- Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L'Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM and Kaspar BK, 2017 Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *N Engl J Med* 377, 1713–1722. doi: 10.1056/NEJMoa1706198. [PubMed: 29091557]
- Mileikovskaya E and Dowhan W, 2014 Cardiolipin-dependent formation of mitochondrial respiratory supercomplexes. *Chem Phys Lipids* 179, 42–8. doi: 10.1016/j.chemphyslip.2013.10.012. [PubMed: 24220496]
- Minkler PE and Hoppel CL, 2010 Separation and characterization of cardiolipin molecular species by reverse-phase ion pair high-performance liquid chromatography-mass spectrometry. *J Lipid Res* 51, 856–65. doi: 10.1194/jlr.D002857. [PubMed: 19965604]
- Monteiro JP, Oliveira PJ and Jurado AS, 2013 Mitochondrial membrane lipid remodeling in pathophysiology: a new target for diet and therapeutic interventions. *Prog Lipid Res* 52, 513–28. doi: 10.1016/j.plipres.2013.06.002. [PubMed: 23827885]
- NCBI, 2019 TAZ tafazzin [*Homo sapiens* (human)] Gene ID: 6901 National Center for Biotechnology Information.
- Neuwald AF, 1997 Barth syndrome may be due to an acyltransferase deficiency. *Curr Biol* 7, R465–6. [PubMed: 9259571]
- Oemer G, Lackner K, Muigg K, Krumschnabel G, Watschinger K, Sailer S, Lindner H, Gnaiger E, Wortmann SB, Werner ER, Zschocke J and Keller MA, 2018 Molecular structural diversity of mitochondrial cardiolipins. *Proc Natl Acad Sci U S A* 115, 4158–4163. doi: 10.1073/pnas.1719407115. [PubMed: 29618609]
- Paradies G, Paradies V, Ruggiero FM and Petrosillo G, 2015 Cardiolipin alterations and mitochondrial dysfunction in heart ischemia/reperfusion injury. *Clinical Lipidology* 10, 415–429.
- Paradies G, Petrosillo G, Pistolesi M and Ruggiero FM, 2002 Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage. *Gene* 286, 135–41. [PubMed: 11943469]
- Pennington ER, Sullivan EM, Fix A, Dadoo S, Zeczycki TN, DeSantis A, Schlattner U, Coleman RA, Chicco AJ, Brown DA and Shaikh SR, 2018 Proteolipid domains form in biomimetic and cardiac mitochondrial vesicles and are regulated by cardiolipin concentration but not monolysocardiolipin. *J Biol Chem* 293, 15933–15946. doi: 10.1074/jbc.RA118.004948. [PubMed: 30158245]
- Petrosillo G, Ruggiero FM and Paradies G, 2003 Role of reactive oxygen species and cardiolipin in the release of cytochrome c from mitochondria. *FASEB J* 17, 2202–8. doi: 10.1096/fj.03-0012com. [PubMed: 14656982]
- Ran Q, Liang H, Gu M, Qi W, Walter CA, Roberts LJ 2nd, Herman B, Richardson A and Van Remmen H, 2004 Transgenic mice overexpressing glutathione peroxidase 4 are protected against oxidative stress-induced apoptosis. *J Biol Chem* 279, 55137–46. doi: 10.1074/jbc.M410387200. [PubMed: 15496407]
- Renner LD and Weibel DB, 2011 Cardiolipin microdomains localize to negatively curved regions of *Escherichia coli* membranes. *Proc Natl Acad Sci U S A* 108, 6264–9. doi: 10.1073/pnas.1015757108. [PubMed: 21444798]
- Reynolds S, 2015 Successful management of Barth syndrome: a systematic review highlighting the importance of a flexible and multidisciplinary approach. *J Multidiscip Healthc* 8, 345–58. doi: 10.2147/JMDH.S54802. [PubMed: 26251611]
- Rigaud C, Lebre AS, Touraine R, Beaupain B, Ottolenghi C, Chabli A, Ansquer H, Ozsahin H, Di Filippo S, De Lonlay P, Borm B, Rivier F, Vaillant MC, Mathieu-Dramard M, Goldenberg A, Viot G, Charron P, Rio M, Bonnet D and Donadieu J, 2013 Natural history of Barth syndrome: a

- national cohort study of 22 patients. *Orphanet J Rare Dis* 8, 70. doi: 10.1186/1750-1172-8-70. [PubMed: 23656970]
- Roberts AE, Nixon C, Steward CG, Gauvreau K, Maisenbacher M, Fletcher M, Geva J, Byrne BJ and Spencer CT, 2012 The Barth Syndrome Registry: distinguishing disease characteristics and growth data from a longitudinal study. *Am J Med Genet A* 158A, 2726–32. doi: 10.1002/ajmg.a.35609. [PubMed: 23045169]
- Ronghe MD, Foot AB, Martin R, Ashworth M and Steward CG, 2001 Non-Epstein-Barr virus-associated T-cell lymphoma following cardiac transplantation for Barth syndrome. *Acta Paediatr* 90, 584–6. [PubMed: 11430723]
- Sabbah HN, Gupta RC, Kohli S, Wang M, Hachem S and Zhang K, 2016 Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. *Circ Heart Fail* 9, e002206. doi: 10.1161/CIRCHEARTFAILURE.115.002206. [PubMed: 26839394]
- Sabbah HN, Gupta RC, Singh-Gupta V and Zhang K, 2019 Effects of elamipretide on skeletal muscle in dogs with experimentally induced heart failure. *ESC Heart Fail* 6, 328–335. doi: 10.1002/ehf2.12408. [PubMed: 30688415]
- Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S, Hawkins ET and Goldstein S, 1991 A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. *Am J Physiol* 260, H1379–84. doi: 10.1152/ajpheart.1991.260.4.H1379. [PubMed: 1826414]
- Saks V, Dzeja P, Schlattner U, Vendelin M, Terzic A and Wallimann T, 2006 Cardiac system bioenergetics: metabolic basis of the Frank-Starling law. *J Physiol* 571, 253–73. doi: 10.1113/jphysiol.2005.101444. [PubMed: 16410283]
- Saric A, Andreau K, Armand AS, Moller IM and Petit PX, 2015 Barth Syndrome: From Mitochondrial Dysfunctions Associated with Aberrant Production of Reactive Oxygen Species to Pluripotent Stem Cell Studies. *Front Genet* 6, 359. doi: 10.3389/fgene.2015.00359. [PubMed: 26834781]
- Schagger H, 2001 Respiratory chain supercomplexes. *IUBMB Life* 52, 119–28. doi: 10.1080/15216540152845911. [PubMed: 11798023]
- Schagger H and Pfeiffer K, 2000 Supercomplexes in the respiratory chains of yeast and mammalian mitochondria. *EMBO J* 19, 1777–83. doi: 10.1093/emboj/19.8.1777. [PubMed: 10775262]
- Schlame M, 2008 Cardiolipin synthesis for the assembly of bacterial and mitochondrial membranes. *J Lipid Res* 49, 1607–20. doi: 10.1194/jlr.R700018-JLR200. [PubMed: 18077827]
- Schlame M, 2013 Cardiolipin remodeling and the function of tafazzin. *Biochim Biophys Acta* 1831, 582–8. doi: 10.1016/j.bbalip.2012.11.007. [PubMed: 23200781]
- Schlame M, Acehan D, Berno B, Xu Y, Valvo S, Ren M, Stokes DL and Epand RM, 2012 The physical state of lipid substrates provides transacylation specificity for tafazzin. *Nat Chem Biol* 8, 862–9. doi: 10.1038/nchembio.1064. [PubMed: 22941046]
- Schlame M, Xu Y and Ren M, 2017 The Basis for Acyl Specificity in the Tafazzin Reaction. *J Biol Chem* 292, 5499–5506. doi: 10.1074/jbc.M116.769182. [PubMed: 28202545]
- Schmidt MR, Birkebaek N, Gonzalez I and Sunde L, 2004 Barth syndrome without 3-methylglutaconic aciduria. *Acta Paediatr* 93, 419–21. [PubMed: 15124852]
- Schnepp BC, Clark KR, Klemanski DL, Pacak CA and Johnson PR, 2003 Genetic fate of recombinant adeno-associated virus vector genomes in muscle. *J Virol* 77, 3495–504. doi: 10.1128/jvi.77.6.3495-3504.2003. [PubMed: 12610125]
- Schug ZT and Gottlieb E, 2009 Cardiolipin acts as a mitochondrial signalling platform to launch apoptosis. *Biochim Biophys Acta* 1788, 2022–31. doi: 10.1016/j.bbamem.2009.05.004. [PubMed: 19450542]
- Shemisa K, Li J, Tam M and Barcena J, 2013 Left ventricular noncompaction cardiomyopathy. *Cardiovasc Diagn Ther* 3, 170–5. doi: 10.3978/j.issn.2223-3652.2013.05.04. [PubMed: 24282766]
- Shi Y, 2010 Emerging roles of cardiolipin remodeling in mitochondrial dysfunction associated with diabetes, obesity, and cardiovascular diseases. *J Biomed Res* 24, 6–15. doi: 10.1016/S1674-8301(10)60003-6. [PubMed: 23554606]

- Soares P, Rocha G, Pissarra S, Soares H, Flor-de-Lima F, Costa S, Moura C, Doria S and Guimaraes H, 2017 Neonatal dilated cardiomyopathy. *Rev Port Cardiol* 36, 201–214. doi: 10.1016/j.repc.2016.10.007. [PubMed: 28256370]
- Sparagna GC, Chicco AJ, Murphy RC, Bristow MR, Johnson CA, Rees ML, Maxey ML, McCune SA and Moore RL, 2007 Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure. *J Lipid Res* 48, 1559–70. doi: 10.1194/jlr.M600551-JLR200. [PubMed: 17426348]
- Speer O, Back N, Buerklen T, Brdiczka D, Koretsky A, Wallimann T and Eriksson O, 2005 Octameric mitochondrial creatine kinase induces and stabilizes contact sites between the inner and outer membrane. *Biochem J* 385, 445–50. doi: 10.1042/BJ20040386. [PubMed: 15294016]
- Spencer CT, Byrne BJ, Bryant RM, Margossian R, Maisenbacher M, Breitenger P, Benni PB, Redfearn S, Marcus E and Cade WT, 2011 Impaired cardiac reserve and severely diminished skeletal muscle O₂ utilization mediate exercise intolerance in Barth syndrome. *Am J Physiol Heart Circ Physiol* 301, H2122–9. doi: 10.1152/ajpheart.00479.2010. [PubMed: 21873497]
- Starkov AA, Andreyev AY, Zhang SF, Starkova NN, Korneeva M, Syromyatnikov M and Popov VN, 2014 Scavenging of H₂O₂ by mouse brain mitochondria. *J Bioenerg Biomembr* 46, 471–7. doi: 10.1007/s10863-014-9581-9. [PubMed: 25248416]
- Steward CG, Groves SJ, Taylor CT, Maisenbacher MK, Versluys B, Newbury-Ecob RA, Ozsahin H, Damin MK, Bowen VM, McCurdy KR, Mackey MC, Bolyard AA and Dale DC, 2019 Neutropenia in Barth syndrome: characteristics, risks, and management. *Curr Opin Hematol* 26, 6–15. doi: 10.1097/MOH.0000000000000472. [PubMed: 30451719]
- Stuart RA, 2008 Supercomplex organization of the oxidative phosphorylation enzymes in yeast mitochondria. *J Bioenerg Biomembr* 40, 411–7. doi: 10.1007/s10863-008-9168-4. [PubMed: 18839289]
- Su B and Ryan RO, 2014 Metabolic biology of 3-methylglutaconic acid-uria: a new perspective. *J Inher Metab Dis* 37, 359–68. doi: 10.1007/s10545-013-9669-0. [PubMed: 24407466]
- Suzuki-Hatano S, Saha M, Rizzo SA, Witko RL, Gosiker BJ, Ramanathan M, Soustek MS, Jones MD, Kang PB, Byrne BJ, Cade WT and Pacak CA, 2019a AAV-Mediated TAZ Gene Replacement Restores Mitochondrial and Cardioskeletal Function in Barth Syndrome. *Hum Gene Ther* 30, 139–154. doi: 10.1089/hum.2018.020. [PubMed: 30070157]
- Suzuki-Hatano S, Saha M, Soustek MS, Kang PB, Byrne BJ, Cade WT and Pacak CA, 2019b AAV9-TAZ Gene Replacement Ameliorates Cardiac TMT Proteomic Profiles in a Mouse Model of Barth Syndrome. *Mol Ther Methods Clin Dev* 13, 167–179. doi: 10.1016/j.omtm.2019.01.007. [PubMed: 30788385]
- Szeto HH, 2014 First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. *Br J Pharmacol* 171, 2029–50. doi: 10.1111/bph.12461. [PubMed: 24117165]
- Tamada T, Feese MD, Ferri SR, Kato Y, Yajima R, Toguri T and Kuroki R, 2004 Substrate recognition and selectivity of plant glycerol-3-phosphate acyltransferases (GPATs) from *Cucurbita moscata* and *Spinacea oleracea*. *Acta Crystallogr D Biol Crystallogr* 60, 13–21. doi: 10.1107/s0907444903020778. [PubMed: 14684887]
- Tang Y, Xia H and Li D, 2018 Membrane Phospholipid Biosynthesis in Bacteria, in: Cao Y (Ed.), *Advances in Membrane Proteins: Part I: Mass Processing and Transportation*. Springer Singapore, Singapore, pp. 77–119. doi: 10.1007/978-981-13-0532-0_4.
- Taylor WA, Mejia EM, Mitchell RW, Choy PC, Sparagna GC and Hatch GM, 2012 Human trifunctional protein alpha links cardiolipin remodeling to beta-oxidation. *PLoS One* 7, e48628. doi: 10.1371/journal.pone.0048628. [PubMed: 23152787]
- Teramoto T, Shirai K, Daida H and Yamada N, 2012 Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. *Cardiovasc Diabetol* 11, 29. doi: 10.1186/1475-2840-11-29. [PubMed: 22439599]
- Thompson WR, DeCroses B, McClellan R, Rubens J, Vaz FM, Kristaponis K, Avramopoulos D and Vernon HJ, 2016 New targets for monitoring and therapy in Barth syndrome. *Genet Med* 18, 1001–10. doi: 10.1038/gim.2015.204. [PubMed: 26845103]
- Tyurina YY, Kini V, Tyurin VA, Vlasova II, Jiang J, Kapralov AA, Belikova NA, Yalowich JC, Kurnikov IV and Kagan VE, 2006 Mechanisms of cardiolipin oxidation by cytochrome c:

- relevance to pro- and antiapoptotic functions of etoposide. *Mol Pharmacol* 70, 706–17. doi: 10.1124/mol.106.022731. [PubMed: 16690782]
- Vaz FM, Houtkooper RH, Valianpour F, Barth PG and Wanders RJ, 2003 Only one splice variant of the human TAZ gene encodes a functional protein with a role in cardiolipin metabolism. *J Biol Chem* 278, 43089–94. doi: 10.1074/jbc.M305956200. [PubMed: 12930833]
- Vernon HJ, Sandler Y, McClellan R and Kelley RI, 2014 Clinical laboratory studies in Barth Syndrome. *Mol Genet Metab* 112, 143–7. doi: 10.1016/j.ymgme.2014.03.007. [PubMed: 24751896]
- Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, Yuan H, Jiang D, Zhang D, Zangi L, Geva J, Roberts AE, Ma Q, Ding J, Chen J, Wang DZ, Li K, Wang J, Wanders RJ, Kulik W, Vaz FM, Laflamme MA, Murry CE, Chien KR, Kelley RI, Church GM, Parker KK and Pu WT, 2014 Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. *Nat Med* 20, 616–23. doi: 10.1038/nm.3545. [PubMed: 24813252]
- Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, de Beer TAP, Rempfer C, Bordoli L, Lepore R and Schwede T, 2018 SWISS-MODEL: homology modelling of protein structures and complexes. *Nucleic Acids Res* 46, W296–W303. doi: 10.1093/nar/gky427. [PubMed: 29788355]
- Whited K, Baile MG, Currier P and Claypool SM, 2013 Seven functional classes of Barth syndrome mutation. *Hum Mol Genet* 22, 483–92. doi: 10.1093/hmg/ddt447. [PubMed: 23100323]
- Woiewodski L, Ezon D, Cooper J and Feingold B, 2017 Barth Syndrome with Late-Onset Cardiomyopathy: A Missed Opportunity for Diagnosis. *J Pediatr* 183, 196–198. doi: 10.1016/j.jpeds.2016.12.070. [PubMed: 28108107]
- Wortmann SB, Duran M, Anikster Y, Barth PG, Sperl W, Zschocke J, Morava E and Wevers RA, 2013 Inborn errors of metabolism with 3-methylglutaconic aciduria as discriminative feature: proper classification and nomenclature. *J Inher Metab Dis* 36, 923–8. doi: 10.1007/s10545-012-9580-0. [PubMed: 23296368]
- Wortmann SB, Kluijtmans LA, Engelke UF, Wevers RA and Morava E, 2012 The 3-methylglutaconic acidurias: what's new? *J Inher Metab Dis* 35, 13–22. doi: 10.1007/s10545-010-9210-7. [PubMed: 20882351]
- Xu Y, Anjaneyulu M, Donelian A, Yu W, Greenberg ML, Ren M, Owusu-Ansah E and Schlame M, 2019 Assembly of the complexes of oxidative phosphorylation triggers the remodeling of cardiolipin. *Proc Natl Acad Sci U S A* 116, 11235–11240. doi: 10.1073/pnas.1900890116. [PubMed: 31110016]
- Xu Y, Malhotra A, Claypool SM, Ren M and Schlame M, 2015 Tafazzins from *Drosophila* and mammalian cells assemble in large protein complexes with a short half-life. *Mitochondrion* 21, 27–32. doi: 10.1016/j.mito.2015.01.002. [PubMed: 25598000]
- Xu Y, Malhotra A, Ren M and Schlame M, 2006 The enzymatic function of tafazzin. *J Biol Chem* 281, 39217–24. doi: 10.1074/jbc.M606100200. [PubMed: 17082194]
- Xu Y, Sutachan JJ, Plesken H, Kelley RI and Schlame M, 2005 Characterization of lymphoblast mitochondria from patients with Barth syndrome. *Lab Invest* 85, 823–30. doi: 10.1038/labinvest.3700274. [PubMed: 15806137]
- Ye C, Shen Z and Greenberg ML, 2016 Cardiolipin remodeling: a regulatory hub for modulating cardiolipin metabolism and function. *J Bioenerg Biomembr* 48, 113–23. doi: 10.1007/s10863-014-9591-7. [PubMed: 25432572]
- Yoda E, Hachisu K, Taketomi Y, Yoshida K, Nakamura M, Ikeda K, Taguchi R, Nakatani Y, Kuwata H, Murakami M, Kudo I and Hara S, 2010 Mitochondrial dysfunction and reduced prostaglandin synthesis in skeletal muscle of Group VIB Ca²⁺-independent phospholipase A2gamma-deficient mice. *J Lipid Res* 51, 3003–15. doi: 10.1194/jlr.M008060. [PubMed: 20625036]
- Zapala B, Platek T and Wybranska I, 2015 A novel TAZ gene mutation and mosaicism in a Polish family with Barth syndrome. *Ann Hum Genet* 79, 218–24. doi: 10.1111/ahg.12108. [PubMed: 25776009]

Zhang M, Mileyskoykaya E and Dowhan W, 2002 Gluing the respiratory chain together. Cardiolipin is required for supercomplex formation in the inner mitochondrial membrane. *J Biol Chem* 277, 43553–6. doi: 10.1074/jbc.C200551200. [PubMed: 12364341]

References Cited: Clinical Case Reports

- Adwani SS, Whitehead BF, Rees PG, Morris A, Turnbull DM, Elliott MJ and de Leval MR, 1997 Heart transplantation for Barth syndrome. *Pediatr Cardiol* 18, 143–5. doi: 10.1007/s002469900135. [PubMed: 9049131]
- Aljishi E and Ali F, 2010 Barth syndrome: an X-linked cardiomyopathy with a novel mutation. *Indian J Pediatr* 77, 1432–3. doi: 10.1007/s12098-010-0222-y. [PubMed: 20981509]
- Alter P and Maisch B, 2007 Non-compaction cardiomyopathy in an adult with hereditary spherocytosis. *Eur J Heart Fail* 9, 98–9. doi: 10.1016/j.ejheart.2006.03.008. [PubMed: 16731037]
- Ances BM, Sullivan J, Weigle JB, Hwang V, Messe SR, Kasner SE and Liebeskind DS, 2006 Stroke associated with Barth syndrome. *J Child Neurol* 21, 805–7. doi: 10.1177/08830738060210090901. [PubMed: 16970891]
- Bachou T, Giannakopoulos A, Trapali C, Vazeou A and Kattamis A, 2009 A novel mutation in the G4.5 (TAZ) gene in a Greek patient with Barth syndrome. *Blood Cells Mol Dis* 42, 262–4. doi: 10.1016/j.bcmd.2008.11.004. [PubMed: 19261493]
- Baksiene M, Benusiene E, Morkuniene A, Ambrozaityte L, Utkus A and Kucinskas V, 2016 A novel intronic splice site tafazzin gene mutation detected prenatally in a family with Barth syndrome. *Balkan J Med Genet* 19, 95–100. doi: 10.1515/bjmg-2016-0043.
- Barth PG, Van den Bogert C, Bolhuis PA, Scholte HR, van Gennip AH, Schutgens RB and Ketel AG, 1996 X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): respiratory chain abnormalities in cultured fibroblasts. *J Inher Metab Dis* 19, 157–60. [PubMed: 8739954]
- Borna NN, Kishita Y, Ishikawa K, Nakada K, Hayashi JI, Tokuzawa Y, Kohda M, Nyuzuki H, Yamashita-Sugahara Y, Nasu T, Takeda A, Murayama K, Ohtake A and Okazaki Y, 2017 A novel mutation in TAZ causes mitochondrial respiratory chain disorder without cardiomyopathy. *J Hum Genet* 62, 539–547. doi: 10.1038/jhg.2016.165. [PubMed: 28123175]
- Bowron A, Honeychurch J, Williams M, Tsai-Goodman B, Clayton N, Jones L, Shortland GJ, Qureshi SA, Heales SJ and Steward CG, 2015 Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype. *J Inher Metab Dis* 38, 279–86. doi: 10.1007/s10545-014-9747-y. [PubMed: 25112388]
- Brady AN, Shehata BM and Fernhoff PM, 2006 X-linked fetal cardiomyopathy caused by a novel mutation in the TAZ gene. *Prenat Diagn* 26, 462–5. doi: 10.1002/pd.1438. [PubMed: 16548007]
- Brion M, de Castro Lopez MJ, Santori M, Perez Munuzuri A, Lopez Abel B, Bana Souto AM, Martinez Soto MI and Couce ML, 2016 Prospective and Retrospective Diagnosis of Barth Syndrome Aided by Next-Generation Sequencing. *Am J Clin Pathol* 145, 507–13. doi: 10.1093/ajcp/aqw025. [PubMed: 27124939]
- Cardonick EH, Kuhlman K, Ganz E and Pagotto LT, 1997 Prenatal clinical expression of 3-methylglutaconic aciduria: Barth syndrome. *Prenat Diagn* 17, 983–8. [PubMed: 9358581]
- Christodoulou J, McInnes RR, Jay V, Wilson G, Becker LE, Lehotay DC, Platt BA, Bridge PJ, Robinson BH and Clarke JT, 1994 Barth syndrome: clinical observations and genetic linkage studies. *Am J Med Genet* 50, 255–64. doi: 10.1002/ajmg.1320500309. [PubMed: 8042670]
- Cosson L, Toutain A, Simard G, Kulik W, Matyas G, Guichet A, Blasco H, Maakaroun-Vermesse Z, Vaillant MC, Le Caignec C, Chantepie A and Labarthe F, 2012 Barth syndrome in a female patient. *Mol Genet Metab* 106, 115–20. doi: 10.1016/j.ymgme.2012.01.015. [PubMed: 22410210]
- Dedieu N, Giardini A, Steward CG, Fenton M, Karimova A, Hsia TY and Burch M, 2013 Successful mechanical circulatory support for 251 days in a child with intermittent severe neutropenia due to Barth syndrome. *Pediatr Transplant* 17, E46–9. doi: 10.1111/petr.12027. [PubMed: 23190323]
- Fan Y, Steller J, Gonzalez IL, Kulik W, Fox M, Chang R, Westerfield BA, Batra AS, Wang RY, Gallant NM, Pena LS, Wang H, Huang T, Bhuta S, Penny DJ, McCabe ER and Kimonis VE, 2013 A

Novel Exonic Splicing Mutation in the TAZ (G4.5) Gene in a Case with Atypical Barth Syndrome. *JIMD Rep* 11, 99–106. doi: 10.1007/8904_2013_228. [PubMed: 23606313]

- Ferri L, Dionisi-Vici C, Taurisano R, Vaz FM, Guerrini R and Morrone A, 2016 When silence is noise: infantile-onset Barth syndrome caused by a synonymous substitution affecting TAZ gene transcription. *Clin Genet* 90, 461–465. doi: 10.1111/cge.12756. [PubMed: 26853223]
- Ferri L, Donati MA, Funghini S, Cavicchi C, Pensato V, Gellera C, Natacci F, Spaccini L, Gasperini S, Vaz FM, Cooper DN, Guerrini R and Morrone A, 2015 Intra-individual plasticity of the TAZ gene leading to different heritable mutations in siblings with Barth syndrome. *Eur J Hum Genet* 23, 1708–12. doi: 10.1038/ejhg.2015.50. [PubMed: 25782672]
- Ferri L, Donati MA, Funghini S, Malvagia S, Catarzi S, Lugli L, Ragni L, Bertini E, Vaz FM, Cooper DN, Guerrini R and Morrone A, 2013 New clinical and molecular insights on Barth syndrome. *Orphanet J Rare Dis* 8, 27. doi: 10.1186/1750-1172-8-27. [PubMed: 23409742]
- Folsi V, Miglietti N, Lombardi A, Boccacci S, Utyatnikova T, Donati C, Squassabia L, Gazzola L, Bosio I, Borghi A, Grassi V, Notarangelo LD and Plebani A, 2014 Cardiomyopathy in a male patient with neutropenia and growth delay. *Ital J Pediatr* 40, 45. doi: 10.1186/1824-7288-40-45. [PubMed: 24887148]
- Hanke SP, Gardner AB, Lombardi JP, Manning PB, Nelson DP, Towbin JA, Jefferies JL and Lorts A, 2012 Left ventricular noncompaction cardiomyopathy in Barth syndrome: an example of an undulating cardiac phenotype necessitating mechanical circulatory support as a bridge to transplantation. *Pediatr Cardiol* 33, 1430–4. doi: 10.1007/s00246-012-0258-z. [PubMed: 22427193]
- Huang SC, Wu ET, Chiu SN, Hwu WL, Wu MH and Wang SS, 2008 Mitral annuloplasty in an infant with Barth syndrome and severe mitral insufficiency: first case report and determination of annular diameter. *J Thorac Cardiovasc Surg* 136, 1095–7. doi: 10.1016/j.jtcvs.2008.01.031. [PubMed: 18954662]
- Huhta JC, Pomerance HH and Barness EG, 2005 Clinicopathologic conference: Barth Syndrome. *Fetal Pediatr Pathol* 24, 239–54. doi: 10.1080/15227950500405429. [PubMed: 16396830]
- Imai-Okazaki A, Kishita Y, Kohda M, Yatsuka Y, Hirata T, Mizuno Y, Harashima H, Hirono K, Ichida F, Noguchi A, Yoshida M, Tokorodani C, Nishiuchi R, Takeda A, Nakaya A, Sakata Y, Murayama K, Ohtake A and Okazaki Y, 2018 Barth Syndrome: Different Approaches to Diagnosis. *J Pediatr* 193, 256–260. doi: 10.1016/j.jpeds.2017.09.075. [PubMed: 29249525]
- Karkucinska-Wieckowska A, Trubicka J, Werner B, Kokoszynska K, Pajdowska M, Pronicki M, Czarnowska E, Lebiecinska M, Sykut-Cegielska J, Ziolkowska L, Jaron W, Dobrzanska A, Ciara E, Wieckowski MR and Pronicka E, 2013 Left ventricular noncompaction (LVNC) and low mitochondrial membrane potential are specific for Barth syndrome. *J Inher Metab Dis* 36, 929–37. doi: 10.1007/s10545-013-9584-4. [PubMed: 23361305]
- Katsushima Y, Fujiwara I, Sakamoto O, Ohura T, Miyabayashi S, Ohnuma A, Yamaguchi S and Iinuma K, 2002 Normal pituitary function in a Japanese patient with Barth syndrome. *Eur J Pediatr* 161, 67–8. [PubMed: 11808885]
- Kelley RI, Cheatham JP, Clark BJ, Nigro MA, Powell BR, Sherwood GW, Sladky JT and Swisher WP, 1991 X-linked dilated cardiomyopathy with neutropenia, growth retardation, and 3-methylglutaconic aciduria. *J Pediatr* 119, 738–47. [PubMed: 1719174]
- Kim GB, Kwon BS, Bae EJ, Noh CI, Seong MW and Park SS, 2013 A novel mutation of the TAZ gene in Barth syndrome: acute exacerbation after contrast-dye injection. *J Korean Med Sci* 28, 784–7. doi: 10.3346/jkms.2013.28.5.784. [PubMed: 23678274]
- Kirwin SM, Vinette KM, Schwartz SB, Funanage VL and Gonzalez IL, 2007 Multiple transmissions of Barth syndrome through an oocyte donor with a de novo TAZ mutation. *Fertil Steril* 87, 976.e5–7. doi: 10.1016/j.fertnstert.2006.07.1543.
- Lindenbaum RH, Andrews PS and Khan AS, 1973 Two cases of endocardial fibroelastosis—possible x-linked determination. *Br Heart J* 35, 38–40. [PubMed: 4685904]
- Man E, Lafferty KA, Funke BH, Lun KS, Chan SY, Chau AK and Chung BH, 2013 NGS identifies TAZ mutation in a family with X-linked dilated cardiomyopathy. *BMJ Case Rep* 2013. doi: 10.1136/bcr-2012-007529.

- Marziliano N, Mannarino S, Nespoli L, Diegoli M, Pasotti M, Malattia C, Grasso M, Pilotto A, Porcu E, Raisaro A, Raineri C, Dore R, Maggio PP, Brega A and Arbustini E, 2007 Barth syndrome associated with compound hemizygosity and heterozygosity of the TAZ and LDB3 genes. *Am J Med Genet A* 143a, 907–15. doi: 10.1002/ajmg.a.31653. [PubMed: 17394203]
- Mazurova S, Tesarova M, Magner M, Houstkova H, Hansikova H, Augustinova J, Tomek V, Vondrackova A, Zeman J and Honzik T, 2013 Novel mutations in the TAZ gene in patients with Barth syndrome. *Prague Med Rep* 114, 139–53. doi: 10.14712/23362936.2014.16.
- McCanta AC, Chang AC and Weiner K, 2008 Cardiomyopathy in a child with neutropenia and motor delay. *Curr Opin Pediatr* 20, 605–7. doi: 10.1097/MOP.0b013e32830a990a. [PubMed: 18781126]
- Momoi N, Chang B, Takeda I, Aoyagi Y, Endo K and Ichida F, 2012 Differing clinical courses and outcomes in two siblings with Barth syndrome and left ventricular noncompaction. *Eur J Pediatr* 171, 515–20. doi: 10.1007/s00431-011-1597-0. [PubMed: 21987083]
- Rigaud C, Lebre AS, Touraine R, Beaupain B, Ottolenghi C, Chabli A, Ansquer H, Ozsahin H, Di Filippo S, De Lonlay P, Borm B, Rivier F, Vaillant MC, Mathieu-Dramard M, Goldenberg A, Viot G, Charron P, Rio M, Bonnet D and Donadieu J, 2013 Natural history of Barth syndrome: a national cohort study of 22 patients. *Orphanet J Rare Dis* 8, 70. doi: 10.1186/1750-1172-8-70. [PubMed: 23656970]
- Ronghe MD, Foot AB, Martin R, Ashworth M and Steward CG, 2001 Non-Epstein-Barr virus-associated T-cell lymphoma following cardiac transplantation for Barth syndrome. *Acta Paediatr* 90, 584–6. [PubMed: 11430723]
- Ronvelia D, Greenwood J, Platt J, Hakim S and Zaragoza MV, 2012 Intrafamilial variability for novel TAZ gene mutation: Barth syndrome with dilated cardiomyopathy and heart failure in an infant and left ventricular noncompaction in his great-uncle. *Mol Genet Metab* 107, 428–32. doi: 10.1016/j.ymgme.2012.09.013. [PubMed: 23031367]
- Rugolotto S, Prioli MD, Toniolo D, Pellegrino P, Catuogno S and Burlina AB, 2003 Long-term treatment of Barth syndrome with pantothenic acid: a retrospective study. *Mol Genet Metab* 80, 408–11. [PubMed: 14654353]
- Sabater-Molina M, Guillen-Navarro E, Garcia-Molina E, Ballesta-Martinez MJ, Escudero F and Ruiz-Espejo F, 2013 Barth syndrome in adulthood: a clinical case. *Rev Esp Cardiol (Engl Ed)* 66, 68–70. doi: 10.1016/j.recsep.2012.05.015. [PubMed: 22999963]
- Sakamoto O, Kitoh T, Ohura T, Ohya N and Iinuma K, 2002 Novel missense mutation (R94S) in the TAZ (G4.5) gene in a Japanese patient with Barth syndrome. *J Hum Genet* 47, 229–31. doi: 10.1007/s100380200030. [PubMed: 12032589]
- Schmidt MR, Birkebaek N, Gonzalez I and Sunde L, 2004 Barth syndrome without 3-methylglutaconic aciduria. *Acta Paediatr* 93, 419–21. [PubMed: 15124852]
- Singh HR, Yang Z, Siddiqui S, Pena LS, Westerfield BH, Fan Y, Towbin JA and Vatta M, 2009 A novel Alu-mediated Xq28 microdeletion ablates TAZ and partially deletes DNL1L in a patient with Barth syndrome. *Am J Med Genet A* 149a, 1082–5. doi: 10.1002/ajmg.a.32822. [PubMed: 19396829]
- Steward CG, Newbury-Ecob RA, Hastings R, Smithson SF, Tsai-Goodman B, Quarrell OW, Kulik W, Wanders R, Pennock M, Williams M, Cresswell JL, Gonzalez IL and Brennan P, 2010 Barth syndrome: an X-linked cause of fetal cardiomyopathy and stillbirth. *Prenat Diagn* 30, 970–6. doi: 10.1002/pd.2599. [PubMed: 20812380]
- Sweeney RT, Davis GJ and Noonan JA, 2008 Cardiomyopathy of unknown etiology: Barth syndrome unrecognized. *Congenit Heart Dis* 3, 443–8. PMID: 19037987. doi: 10.1111/j.1747-0803.2008.00226.x. [PubMed: 19037987]
- Takeda A, Sudo A, Yamada M, Yamazawa H, Izumi G, Nishino I and Ariga T, 2011 Barth syndrome diagnosed in the subclinical stage of heart failure based on the presence of lipid storage myopathy and isolated noncompaction of the ventric ventricular myocardium. *Eur J Pediatr* 170, 1481–4. doi: 10.1007/s00431-011-1576-5. [PubMed: 21932011]
- Thiels C, Flegler M, Huemer M, Rodenburg RJ, Vaz FM, Houtkooper RH, Haack TB, Prokisch H, Feichtinger RG, Lucke T, Mayr JA and Wortmann SB, 2016 Atypical Clinical Presentations of TAZ Mutations: An Underdiagnosed Cause of Growth Retardation? *JIMD Rep* 29, 89–93. doi: 10.1007/8904_2015_525. [PubMed: 26724946]

- Valianpour F, Wanders RJ, Overmars H, Vreken P, Van Gennip AH, Baas F, Plecko B, Santer R, Becker K and Barth PG, 2002 Cardiolipin deficiency in X-linked cardioskeletal myopathy and neutropenia (Barth syndrome, MIM 302060): a study in cultured skin fibroblasts. *J Pediatr* 141, 729–33. doi: 10.1067/mpd.2002.129174. [PubMed: 12410207]
- Vesel S, Stopar-Obreza M, Trebusak-Podkrajsek K, Jazbec J, Podnar T and Battelino T, 2003 A novel mutation in the G4.5 (TAZ) gene in a kindred with Barth syndrome. *Eur J Hum Genet* 11, 97–101. doi: 10.1038/sj.ejhg.5200926. [PubMed: 12529714]
- Wang J, Guo Y, Huang M, Zhang Z, Zhu J, Liu T, Shi L, Li F, Huang H and Fu L, 2017 Identification of TAZ mutations in pediatric patients with cardiomyopathy by targeted next-generation sequencing in a Chinese cohort. *Orphanet J Rare Dis* 12, 26. doi: 10.1186/s13023-016-0562-4. [PubMed: 28183324]
- Woiewodski L, Ezon D, Cooper J and Feingold B, 2017 Barth Syndrome with Late-Onset Cardiomyopathy: A Missed Opportunity for Diagnosis. *J Pediatr* 183, 196–198. doi: 10.1016/j.jpeds.2016.12.070. [PubMed: 28108107]
- Yen TY, Hwu WL, Chien YH, Wu MH, Lin MT, Tsao LY, Hsieh WS and Lee NC, 2008 Acute metabolic decompensation and sudden death in Barth syndrome: report of a family and a literature review. *Eur J Pediatr* 167, 941–4. doi: 10.1007/s00431-007-0592-y. [PubMed: 17846786]
- Yoo TY, Kim MR, Son JS, Lee R, Bae SH, Chung S, Kim KS, Seong MW and Park SS, 2016 Identification of a Novel De Novo Mutation of the TAZ Gene in a Korean Patient with Barth Syndrome. *J Cardiovasc Ultrasound* 24, 153–7. doi: 10.4250/jcu.2016.24.2.153. [PubMed: 27358708]
- Zapala B, Platek T and Wybranska I, 2015 A novel TAZ gene mutation and mosaicism in a Polish family with Barth syndrome. *Ann Hum Genet* 79, 218–24. doi: 10.1111/ahg.12108. [PubMed: 25776009]

Highlights

- *TAZ* encodes the tafazzin transacylase responsible for cardiolipin (CL) remodeling.
- Tafazzin localizes to the mitochondrial membranes for direct access to CL.
- Tafazzin generates mature CL to maintain mitochondrial structure-function.
- Mutations throughout *TAZ* cause the rare mitochondrial disease Barth syndrome.
- There is no cure for Barth syndrome, but PPAR agonists, AAV9 gene therapy, CL protection, and protection from oxidative stress are in development.

Figure 1. *TAZ* genetic mutations, frequency and pathogenicity.

The frequency of intronic and exonic mutations across the length of the *TAZ* gene are shown here, categorized by pathogenicity and mapped to the nucleotide (nt) position on the gene, with exons represented by thick grey bars below the x-axis. Patient mutation data was acquired from the Barth Syndrome Foundation *TAZ* database (<https://barthsyndrome.org/research/tazdatabase.html>).

Figure 2. Tafazzin domains, mutation frequency, and mutation type.

The frequency of pathogenic, exonic mutations across the length of the tafazzin protein are shown here, categorized by mutation type, with key functional domains of the tafazzin protein displayed below the x-axis. Tafazzin contains a transmembrane helix (TM helix) and a membrane anchor at positions 15-34 and 215-232, respectively. The acyltransferase active site spans 176 amino acids (aa) from residue 41-217, with His77 forming part of the His-Asp motif (HX₄D). Mitochondrial targeting domains are encoded in exon 3 as well as exon 7/8, spanning protein residues 84-95 and 185-220, respectively. Patient mutation data was acquired from the Barth Syndrome Foundation *TAZ* database (<https://www.barthsyndrome.org/research/tazdatabase.html>).

Figure 3. Mechanism of acyltransferase activity by tafazzin.

Tafazzin acts as a shuttle for specific acyl groups between different phospholipids to generate mature cardiolipin. Tafazzin transfers an acyl side chain from a phospholipid such as phosphatidylcholine (PC) to reacylate monolysocardiolipin (MLCL) in a single-step acyl group transfer reaction, resulting in the formation of lysophosphatidylcholine (LPC) and the mature tetralinoleoyl form of cardiolipin. The red acyl side chains indicate the acyl group that is transferred by tafazzin, and the blue circles indicate the location on MLCL where the new acyl chain is added to form the mature tetralinoleoyl cardiolipin.

Figure 4. Complex symptomology of Barth syndrome codified by ICD-10.

Symptom occurrence codified using the 10th edition of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) from 133 Barth syndrome patients described in 54 clinical case reports (please see **References Cited: Clinical Case Reports**). Panel (A) presents the full collection of 997 instances of 206 unique ICD-10 codes across all patients in these reports, grouped by disease category (Caufield et al., 2018b; Caufield et al., 2018a). Cardiovascular diseases and symptoms are the most highly represented among all ICD-10 categories ($n = 272$). Panel (B) highlights the top 10 symptoms from all ICD-10 categories. Panel (C) depicts the top 10 cardiovascular symptoms. All data is housed on the MitoCases platform (<http://mitocases.org/>) along with detailed metadata on the medical information contained in the text of each CCR.

Table 1.
Essential properties and identifiers of *TAZ* and tafazzin.

The table contains a summary of the essential properties, identifiers, and names of the *TAZ* gene and the encoded tafazzin protein in *Homo sapiens* (human) and *Mus musculus* (mouse) (NCBI, 2019).

Species	<i>Homo sapiens</i> (human)	<i>Mus musculus</i> (mouse)
Gene	<i>TAZ</i>	<i>TAZ</i>
Synonyms	BTHS, EFE, EFE2, CMDA3, LVNCX, G4.5	5031411C02Rik, 9130012G04Rik, AW107266, AW552613, G4.5
NCBI Gene ID	6901	66826
Chromosomal location	chrXq28:154,411,524-154,421,726	chrX:74,282,697-74,290,151
Length (nt)	10,171	7,454
Exons/Introns	11/10	10/9
NCBI Gene ID	6901	66826
UniProt ID	Q16635	I7HJS2
Ensembl ID	ENSG00000102125	ENSMUST00000069722.12
Length (aa)	292	263
Molecular weight (Da)	33,459	30,433